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Summary
This thesis examines the metabolic interactions between alcohol and the liver and 
gastrointestinal tract. The metabolism of alcohol by the liver and gastrointestinal 
tract may determine susceptibility to alcohol- related disease, but is also likely to be 
responsible for alcohol related damage to these organs.
The three introductory chapters review the current understanding of alcohol related 
gastrointestinal and liver disease and alcohol metabolism. Chapter 1 reviews the 
epidemiology of alcohol consumption and alcohol related disease, and then 
discusses in detail the hepatic and gastrointestinal lesions associated with alcohol. 
Differing patterns of genetic and environmental susceptibility are then discussed, 
followed by a detailed review of the processes involved in alcohol metabolism, 
focussing on pathogenic mechanisms related to metabolism (i.e. redox shift, hepatic 
hypermetabolism, acetaldehyde induced damage, free- radical generation, 
cytochrome induction, antioxidant, phospholipid and vitamin depletion, endotoxin- 
mediated damage and mechanisms of hepatic fibrogenesis).
Chapter 2 concentrates on alcohol dehydrogenase, which is quantitatively the most 
important enzyme involved in alcohol metabolism. The complex nomenclature of 
alcohol dehydrogenase is discussed. Genetic and environmental influences on 
hepatic and extra-hepatic alcohol dehydrogenase are discussed. The evidence 
regarding the controversial role of gastric alcohol dehydrogenase in determining
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susceptibility to alcohol related disease, and the genetic and environmental factors 
that affect its activity, is reviewed in detail. Conventional methods of determining 
the activity of alcohol dehydrogenase experimentally are discussed.
The complex pharmacokinetics of alcohol are reviewed in detail in Chapter 3. The 
validity of common assumptions made by researchers examining alcohol 
metabolism is discussed, and illustrated by using specific examples. This chapter 
concludes that pharmacokinetic principles based on linear elimination kinetics 
cannot be applied to studies of alcohol metabolism. The rate of delivery of alcohol 
to the systemic circulation will partly determine its bioavailability.
Chapter 4 states the aims of this thesis. The first major aim is to determine if a rise 
in gastric alcohol dehydrogenase activity following Helicobacter pylori eradication 
is associated with any change in the pre-systemic metabolism of alcohol, and to 
determine to what extent this is influenced by changes in gastric emptying. A 
secondary aim of this thesis is to develop an improved assay for gastric alcohol 
dehydrogenase activity. The second major aim of this thesis is to determine if there 
is any evidence from conventional biochemical liver function tests or plasma 
markers of hepatic fibrogenesis for hepatic damage following abrupt alcohol 
withdrawal.
The fifth chapter describes in detail the development of a rapid, colorimetric, semi­
automated assay for gastric alcohol dehydrogenase. Use of a coupled enzymatic 
colorimetric reaction results in an increased sensitivity that has facilitated
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replacement of the conventional (time- consuming) homogenisation stage with an 
incubation stage. Data from experiments designed to determine the optimum assay 
conditions, and to demonstrate the sensitivity, specificity, and reproducibility of the 
new method are provided, and the new method is compared with conventional 
methods. A normal range for gastric alcohol dehydrogenase activity by this new 
assay method is provided.
In chapter 6, the effect of Helicobacter pylori eradication on alcohol metabolism and 
gastric alcohol dehydrogenase activity is assessed. There is a marked increase in 
gastric antral alcohol dehydrogenase activity following Helicobacter eradication, 
although this does not result in a significant change in alcohol first pass metabolism, 
or the degree of systemic exposure to alcohol. Gastric emptying (assessed by 
paracetamol absorption) does not change following eradication. Alcohol 
bioavailability correlates with gastric emptying but not with gastric alcohol 
dehydrogenase activity.
Evidence for hepatic damage following abrupt alcohol withdrawal in subjects who 
are alcoholics, but have, at worst, well- compensated liver disease is sought in the 
experiments described in Chapter 7. Although there is no worsening of hepatic 
transaminases following alcohol withdrawal when considering the group of subjects 
as a whole, 32% of subjects did meet pre- defined criteria for worsening of 
transaminases. Concomitant intake of a small dose of paracetamol during the 
withdrawal period was associated with a marked transaminase rise. High basal 
levels, of, and changes following alcohol withdrawal, of plasma levels of
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aminoterminal procollagen HI peptide suggest that alcoholics may have reduced 
degradation of collagen whilst still drinking, and may have increased deposition of 
collagen, or a reduction in hepatic clearance, following alcohol withdrawal. High 
levels of tissue inhibitor of metal loproteinases-1 in alcoholics, which did not change 
following alcohol withdrawal, suggest that there may be inhibition of collagen 
degradation even in alcoholics who have, at worst, clinically compensated liver 
disease.
This thesis has three major conclusions. Firstly, it concludes that the colorimetric 
technique described for assaying gastric alcohol dehydrogenase activity can offer 
significant advantages over conventional methods. Secondly, although Helicobacter 
eradication increases gastric alcohol dehydrogenase activity, there is no change in 
alcohol bioavailability, suggesting that this enzyme plays at most a minor role in 
determining alcohol bioavailability. Thirdly, the minor changes in hepatic 
transaminases and markers of fibrosis following alcohol withdrawal may reflect 
mild liver injury; with perhaps a minor tendency to increased fibrosis or decreased 
hepatic clearance. The cumulative effect of repeated episodes of abrupt alcohol 
withdrawal may therefore be clinically significant, although this would require 
clarification by further studies.
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SECTION 1 INTRODUCTION AND AIMS
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Chapter 1: The interaction between alcohol and the liver and gastrointestinal 
tract
1.1 Introduction
Excessive alcohol consumption is a major cause of morbidity and mortality (Lieber, 
1995). Approximately 3.5% of the total burden of disease worldwide has been 
attributed to the effects of alcohol (Murray and Lopez, 1997). The association 
between the consumption of alcohol and physical disease has been recognised since 
ancient times (Jellinek, 1976). Andreas Vesalius, the renaissance anatomist, 
described the association between alcohol and liver cirrhosis in the sixteenth century 
(Franken and Falk, 1991). Chronic alcohol abuse can predispose to disease in all of 
the major organ systems. The relationship between alcohol and the liver and 
gastrointestinal (GI) tract is particularly interesting because these are the major sites 
both of alcohol related damage and alcohol metabolism. Hepatic and GI alcohol 
metabolism may therefore be important in determining an individual’s overall 
susceptibility to alcohol related disease.
In this chapter, I will briefly consider the epidemiology of alcohol consumption and 
disease before discussing the liver and GI tract lesions associated with alcohol. I will 
then outline the patterns of susceptibility to alcohol induced hepatic and GI damage 
before discussing in detail the pathogenic mechanisms, which are often linked to 
alcohol metabolism.
Page 16
1.2 Epidemiology
Total alcohol consumption fell in most European countries from 1870 until World 
War n, but subsequently rose again until the 1980’s. Over the period 1987- 1998, 
total alcohol consumption in the UK calculated from legal sales has remained static, 
at approximately 9.8 litres of pure alcohol per person aged over 15 years per annum. 
However, certain sub-groups of the U.K. population, notably women and 11-15 year 
olds of both sexes, have recently shown increased rates of consumption. In 1996, 
27% of men and 14% of women in the UK consumed more than 168g and 112g of 
alcohol per week, respectively (Department of Health, 1999).
Heavy alcohol consumption is linked to an increase in total mortality. However, 
modest alcohol intake (less than 20-3Og per day) is associated with lower all- cause 
mortality than complete abstinence (Dawson, 2000), (Doll et al., 1994), (Fuchs et 
al., 1995). This “J-shaped” mortality curve appears to be mainly due to fewer deaths 
from coronary heart disease, and is more marked in males (Doll et al., 1994) than 
females (Fuchs et al., 1995). A highly significant positive correlation has been 
demonstrated between alcohol consumption and death rates from cirrhosis both at a 
national level (Smart, 1984), (Pequignot, 1960), (Terris, 1967), (Nordstrom, 1987), 
and in smaller populations. An association between alcohol consumption and deaths 
from neoplasia, particularly of the upper GI tract has also been observed (Doll et al., 
1994), (Fuchs et al., 1995). Fluctuations in per capita consumption of alcohol result 
in corresponding changes in cirrhosis death rates. Restrictions on alcohol availability 
are associated with a lower death rate from cirrhosis, for example following
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licensing restrictions during World War I in the United Kingdom (Smart, 1984), 
following wine rationing during World War II in France (Pequignot, 1960), during 
prohibition in the United States (1919- 1932) (Terris, 1967), and before the end of 
alcohol rationing in Sweden in 1955 (Nordstrom, 1987).
1.3 Hepatic lesions associated with alcohol
Alcohol excess is associated with a wide spectrum of disease in the liver. Alcoholic 
liver injury usually progresses from fatty liver (alcoholic steatosis), through 
alcoholic hepatitis to cirrhosis. All three lesions can coexist, and in some cases, 
cirrhosis may develop without preceding evidence of alcoholic hepatitis.
1.3.1 Fatty liver
Fatty liver is the most commonly encountered lesion in alcoholic liver disease, 
occurring in 60-95% of chronic alcoholics (French et a l, 1993). It is characterised 
histologically as an increase in fat deposition within hepatocytes, and is 
accompanied by an increase in hepatocyte and total liver size. The fat is most often 
deposited as large, often single, droplets (macrovesicular steatosis), although less 
commonly smaller droplets may occur (microvesicular steatosis or alcoholic foamy 
degeneration). Microvesicular steatosis is more often associated with hepatic
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mitochondrial damage and may progress more readily to cirrhosis than 
macrovesicular steatosis (Uchida et al., 1983). Mitochondrial damage is a striking 
feature of alcoholic liver disease, with giant mitochondria seen in 25% of cases. 
Fatty liver has been shown to develop within as little as 8 days of heavy drinking 
(Lieber et al., 1965) and is usually reversible, regressing after approximately one 
month of abstinence from alcohol.
1.3.2 Alcoholic hepatitis
Estimates of the prevalence of alcoholic hepatitis amongst heavy drinkers vary 
according to the population studied and the method of diagnosis. In those drinking 
more than 160g of alcohol daily who come into contact with medical services 
approximately 30-40% have evidence of alcoholic hepatitis (Lelbach, 1975b). 
Overall, it is estimated that 10- 35% of those with fatty liver will progress to 
alcoholic hepatitis after a period of excess alcohol consumption of 15- 20 years 
(Morgan and Sherlock, 1977). Histologically there is swelling, ballooning, and 
necrosis of hepatocytes and an inflammatory response that consists predominantly of 
neutrophils. Mallory’s hyaline is an irregular cytoplasmic deposit of eosin- staining 
material in hepatocytes and is usually considered the hallmark of alcoholic hepatitis, 
although this is not seen in all cases, and may rarely be seen in liver damage of 
another cause. Alcoholic hepatitis reverses following abstinence in approximately 
30- 40% of cases. However, approximately one third of cases of alcoholic hepatitis
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progress to cirrhosis despite abstinence. This is more likely in women, and those 
with severe alcoholic hepatitis on initial biopsy (Pares et al, 1986).
1.3.3 Cirrhosis
A net increase in the deposition of fibrous tissue in the liver following chronic injury 
leads to cirrhosis. Fibrous septa link hepatic vein branches, and hepatic vein 
branches to portal vein branches. The normal liver architecture is lost and 
regenerative activity in hepatocytes leads to nodule formation. Cirrhosis was 
traditionally considered to be irreversible, although there are reports of cirrhosis 
reversal, particularly when is at an early stage (Perez-Tamayo, 1979), (Iredale et al, 
1998). Recent insights have suggested mechanisms at a cellular and molecular level 
by which cirrhosis could reverse or partially regress (Benyon and Iredale, 2000), and 
these will be discussed in more detail later. Perivenular fibrosis is fibrous thickening 
around the central hepatic venules and is an early histological marker for the later 
development of cirrhosis, which may occur without significant evidence of alcoholic 
hepatitis in the intervening period (Van Waes and Lieber, 1977). Only 10- 20% of 
heavy drinkers with fatty liver will develop cirrhosis (Sorensen et a l, 1984).
Estimates of the level of alcohol consumption required to produce cirrhosis have 
varied widely in different studies. Older studies tend to estimate the cirrhotogenic 
threshold more highly. They suggest that ingestion of around 160- 200g of alcohol 
daily for 20 years will result in 50% of subjects developing cirrhosis, an
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approximate cumulative lifetime dose of 600kg of alcohol for men, and 150- 300kg 
in women (Lelbach, 1975a). Studies that are more recent suggest a threshold as low 
as 40g of alcohol per day for men and 20g per day for women for cirrhosis (Tuyns 
and Pequignot, 1984). Alcohol associated liver lesions were not seen with 
consumption of less than 30g of alcohol per day in the Dionysos study, a large 
Italian cohort study (Bellentani et al, 1997).
Once the cirrhotogenic threshold has been reached, the risk of cirrhosis does not 
significantly increase with further alcohol consumption beyond 160g of alcohol per 
day, suggesting that a critical dose of alcohol has a permissive role in establishing 
conditions for the development of cirrhosis, which depends on the presence of other 
factors (Sorensen e ta l, 1984).
Hepatocellular carcinoma may arise in up to 15% of patients with alcoholic 
cirrhosis. Cirrhosis, and to a lesser extent alcoholic hepatitis, leads to portal 
hypertension causing the development of porto-systemic collaterals and shunting 
with the attendant complications of hepatic encephalopathy, varices, and ascites 
which are major causes of mortality in advanced liver disease.
1.4 Gastrointestinal lesions associated with alcohol
Alcohol abuse predisposes to a variety of GI tract lesions, although damage to these 
organs is also unpredictable, despite heavy alcohol intake.
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1.4.1 Oesophagus
Alcohol abuse is associated with acute and chronic oesophagitis (Krasner, 1977a). 
Alcohol can cause direct oesophageal mucosal damage. Acute ingestion of alcohol, 
especially with food, decreases lower oesophageal sphincter pressure leading to 
increased gastro- oesophageal reflux (Kaufman and Kaye, 1978). Chronic alcohol 
ingestion is associated with altered oesophageal motility leading to a decrease in the 
rate of oesophageal acid clearance, thus precipitating reflux oesophagitis and 
predisposing to Barrett’s oesophagus. The Mallory- Weiss lesion, a linear mucosal 
tear, is a common traumatic lesion of the gastro-oesophageal junction induced by 
retching after alcohol binges. There is an increased risk of upper GI tract neoplasia, 
particularly oropharyngeal and oesophageal carcinoma (a relative risk of 5 in those 
who drink heavily compared with abstainers (Gronbaek et al, 1998)). There is a 
synergistic relationship between alcohol and tobacco in the risk of developing these 
lesions.
1.4.2 Stomach and duodenum
William Beaumont initially recorded that alcohol causes acute haemorrhagic 
inflammation of the gastric mucosa in 1833 in a series of experiments involving 
direct visualisation of the mucosa through a gastrostomy (discussed in (Valencia-
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Parparcen, 1981)). Alcohol may initiate inflammation through a direct chemical 
effect, through decreased mucosal resistance to acid, through decreased 
prostaglandin production (Bode et al., 1996), or by alcohol metabolites such as 
acetaldehyde that may be produced either by gastric mucosa or by Helicobacter 
pylori (HP) (Roine et al., 1992b). Fermented, but not distilled alcoholic drinks are 
powerfijl stimulants of gastric acid secretion (Teyssen et al., 1997). Acute alcoholic 
gastritis will usually resolve within 72 hours of abstinence. The role of alcohol in 
contributing to chronic gastritis is less clear. Chronic alcohol abuse was previously 
though to cause a chronic atrophic gastritis, although the discovery of the role of HP 
in chronic gastritis has changed this view, as most chronic gastritis in chronic 
alcoholics will respond to HP eradication but not to abstinence (Uppal et al., 1991).
Alcohol abuse does not predispose to peptic ulceration, except in the presence of 
alcoholic cirrhosis (Kirk et al., 1980), where the aetiology of peptic ulcer may be 
different to that in non- cirrhotics. The association between peptic ulcer and HP 
infection is less marked in cirrhotics, and rates of ulcer healing are lower, than in 
non- cirrhotics (Tsai, 1998). The net effect of alcohol consumption on gastric 
motility remains unclear, with studies showing contradictory findings (reviewed in 
(Bujanda, 2000)).
The antiseptic properties of alcohol may confer an advantage on alcohol drinkers in 
terms of lower gastrointestinal infection rates. In the past, wine consumption in 
particular was advocated for the prevention of infectious disease. Wine is 
bactericidal îovSalmonella species in vitro (Marimon e ta l, 1998). The relative risk
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of HP infection is lower in those with greater alcohol consumption (Brenner et al., 
1997).
1.4.3 Pancreas
Friedreich first described chronic alcoholic pancreatitis in detail in 1878 (described 
in (Thiel et al., 1981)). The risk of developing pancreatitis rises with increasing 
alcohol consumption, and is positively associated with the protein and fat content of 
the diet in alcoholics (Sarles et al., 1973). Some consider that acute alcoholic 
pancreatitis is only a single episode that may recur during the course of chronic 
alcoholic pancreatitis that may be clinically occult. However, isolated acute lesions 
do occasionally occur after a bout of alcoholism in people who otherwise have a 
very low alcohol intake (Strum and Spiro, 1971).
Chronic alcohol abuse causes patchy inflammation of pancreatic acini, with 
resulting areas of necrosis, fibrosis, ductal narrowing, and dilatation. Precipitates of 
protein and calcium carbonate form in the pancreatic ducts. With progressive 
fibrosis of there is loss of pancreatic exocrine function, and in severe cases loss of 
endocrine function. Progressive destruction of the pancreas continues even after 
abstinence. The risk of pancreatic carcinoma rises with heavy alcohol intake (Burch 
and Ansari, 1968).
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1.4.4 Small intestine, colon, and rectum.
The effects of alcohol on the small and large intestine are less specific and include 
alterations in gut motility and permeability, altered sodium, micronutrient and water 
absorption by ATP- dependent transport mechanisms, and altered mucosal protein 
synthesis (Nakshabendi e ta l, 1995) leading to diminished brush border enzyme 
activity (Perlow et a l, 1977). Haemorrhagic lesions in duodenal and small bowel 
villous tips are seen after acute ethanol ingestion. These usually heal within 12- 24 
hours (Pirola et al, 1969). The overall consequence of these effects is to cause 
diarrhoea, promote nutrient deficiencies, and increase specific dietary nutrient 
requirements.
The data regarding the risk of colorectal carcinoma in alcohol drinkers is unclear, 
with some studies suggesting an increased relative risk of carcinoma or 
adenomatous polyps (Cope et al, 1991) whilst others finding no increased risk 
(Tavani e ta l, 1998).
1.5 Environmental factors associated with alcohol related damage
From this overview of alcohol- related diseases affecting the liver and GI tract, it 
can be appreciated that whilst there is an association between the amount of alcohol 
consumed and physical disease, the onset and severity of illness depends on more 
than the period and extent of alcohol abuse. I will therefore review the
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environmental and genetic factors that are associated with a predisposition to 
alcohol related disease, before considering in detail the potential mechanisms for 
these patterns of susceptibility. It is important to distinguish between factors that 
may predispose to increased alcohol consumption, and others that predispose to 
increased susceptibility to alcohol- related disease for a given level of alcohol 
consumption.
1.5.1 Type of alcoholic beverage
In general, it has been assumed that the nature of alcohol consumed (e.g. beer, wine, 
spirits) was not important in determining susceptibility to alcoholic liver disease. 
However, the Dionysos study suggested that after adjusting for total consumption, 
those consuming multiple types of alcoholic beverage might be more at risk than 
those drinking one type only (Bellentani et al., 1997). Another recent study has 
found a non- significant trend towards higher lifetime consumption of spirits in 
alcoholics with liver disease (Dear et al, 2001).
There is evidence that the type of beverage may be important in determining GI tract 
lesions. The relative risk of upper GI tract (Gronbaek et al, 1998) and colorectal 
(Anderson et al, 2001) neoplasia in alcoholics is less marked in wine drinkers than 
in spirit or beer drinkers. In carcinoma of the pancreas, the increased risk with 
alcohol is largely related to beer consumption (Cuzick and Babiker, 1989). These 
findings of an attenuation of increased carcinoma risk with wine consumption may
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relate to the large quantity of antioxidant polyphenols in wine that have some 
potential anti-tumour properties.
1.5.2 Pattern of alcohol consumption
The pattern of consumption (intermittent binging versus chronic consumption) may 
have some importance in liver disease, with those who have a continuous higher 
consumption (Brunt et al., 1974) and those who consume alcohol outside mealtimes 
(Bellentani et al, 1997) at more risk of physical disease. This may be related to an 
increased first pass metabolism of alcohol when it is consumed with food.
In some alcoholics, abrupt alcohol withdrawal will cause delirium tremens, a 
syndrome of profound cardiovascular and neurological excitability. Severe delirium 
tremens is associated with a high mortality rate if it is untreated (Adinoff et al, 
1988). There is some evidence that abrupt alcohol withdrawal may also predispose 
to liver damage, particularly in subjects with alcoholic hepatitis (Marshall et al, 
1983), (Salum, 1972), (Sabesin et al, 1978), (Helman et al, 1971).
1.5.3 Nutritional factors
Malnutrition often coexists with alcohol related disease. It is often difficult to 
determine cause and effect when considering the link between alcohol related
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disease and nutritional status, although the evidence for a link between malnutrition 
and disease severity is strong. Prior to the onset of clinically apparent disease, the 
overall nutritional status of alcoholics is not markedly inferior to non- alcoholics 
except in the presence of significant social deprivation, although approximately 5% 
may have some evidence of specific, usually single, nutrient deficiencies (Salaspuro, 
1993). However, once there is evidence of physical damage secondary to alcohol, 
the severity of malnutrition varies directly with disease severity. For example, 
almost all subjects in studies of alcoholic hepatitis have some evidence of 
malnutrition, and the severity of malnutrition varied directly with hepatitis severity 
and mortality (Mendenhall e ta l, 1984).
Alcoholism may cause primary malnutrition by displacing nutrients in a diet 
consisting largely of alcohol. Despite being a source of energy (7 Calories per 
gram), alcohol is often considered nutritionally empty. In animal studies, growth 
rates are poorer in animals receiving a proportion of their energy from alcohol 
compared to those on an iso-caloric, non- alcohol diet (Lieber et al., 1965). In 
alcoholics, the provision of a weight- maintenance diet with supplementary calories 
in the form of alcohol fails to produce an increase in body weight (Pirola and Lieber, 
1972).
Secondary malnutrition can occur due to the effects of alcohol on pancreatic or 
small bowel function discussed earlier. Acquired nutritional deficiencies may result 
from altered metabolism or molecular transport causing a non- essential
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micronutrient to become essential. An example of this will be discussed later in the 
context of methionine.
Alcoholic liver disease was once thought to be primarily due to associated 
malnutrition. Rat studies from the 1940's using a diet with 10- 25% of total calories 
from alcohol showed that liver lesions developed only if the animals were fed a 
protein or choline deficient diet (Best et al., 1949). The introduction of a complete 
liquid diet supplemented with alcohol (the Lieber- DeCarli diet) allowed higher 
alcohol intakes of around 36% of total calories to be achieved and this was 
associated with development of &tty liver in nutritionally replete rats (Lieber et al,
1965). In the same paper, the authors report that administration of alcohol under 
controlled conditions to otherwise abstinent former alcoholics resulted in the 
development of fatly liver. More severe liver lesions can be reproduced in rats by 
prolonged intra-gastric infusions of ethanol (French, 2001).
It has not been possible to reproduce the exact range of hepatic lesions in animals 
that are seen in alcoholic liver disease in man. However, studies using the Lieber- 
DeCarli diet in baboons have shown that lesions very similar to human alcoholic 
cirrhosis can occur with chronic alcohol excess and a nutritionally adequate diet 
(Lieber and DeCarli, 1974).
The risk of alcoholic liver disease rises with increasing dietary fat (reviewed by 
(French, 1993)), and there is an association between obesity and alcoholic steatosis, 
hepatitis, and cirrhosis (Naveau et al, 1997). Polyunsaturated fat may be more
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important than saturated fat in determining the susceptibility to liver disease. 
Polyunsaturated fatty acids (PUFA) are more prone to peroxidation than saturated 
fats and induce alcohol metabolising enzymes (Wade et al., 1985). Peroxidative 
damage is also more likely to occur in those with deficient diets due to impaired 
antioxidant defences.
The importance of malnutrition in physical disease outside the liver, e.g. thiamine 
deficiency and Wernicke's encephalopathy, is well established.
1.5.4 Hepatic and gastrointestinal infection
Co-exiting liver disease as a result of chronic viral hepatitis may influence the 
progression of alcoholic liver injury. The prevalence of serum antibodies suggesting 
previous hepatitis B exposure in patients with alcoholic cirrhosis was estimated at 
approximately 30% in Scotland in 1981 (Mills et al., 1981), and 30% in the United 
states in 1991 (Mendenhall et al., 1991). The widespread vaccination for hepatitis B 
may have changed the prevalence of this infection. Alcoholics with hepatitis B tend 
to present with cirrhosis at a younger age (Ohnishi et al, 1982), although other 
studies suggest that markers of hepatitis B infection are unrelated to the severity of 
liver injury (Mendenhall e t a l , 1991). However, the same study, and an Italian study 
(Loguercio et al, 2000), found that hepatitis C infection was associated with more 
severe liver disease in alcoholics. The prevalence of hepatitis C in alcoholics varies 
widely, being nil in a West of Scotland study (Bird et al, 1995), and approximately
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5% in a male US population (Mendenhall et al, 1991). Alcohol abuse is associated 
with higher levels of hepatitis C virus RNA, and with a decreased response rate to 
interferon therapy (Loguercio et al, 2000).
Gastrointestinal bacteria are capable of metabolising alcohol, which may promote 
GI damage or carcinogenesis. Intestinal bacteria may also directly contribute to liver 
damage by increased bacterial translocation. It has been suggested that urea 
metabolism to ammonia by HP may increase the risk of hepatic encephalopathy in 
alcoholic liver disease (Mendenhall et al, 1993), although this has not been 
confirmed by later studies (Calvert et al, 2001).
1.6 Genetic factors associated with alcohol related damage
1.6.1 Family and twin studies
Almost all family studies have shown higher rates of alcoholism among relatives of 
alcoholics than in the general population (Jenkins and Thomas, 1981). In an attempt 
to separate common genetic from environmental factors in families, studies in 
mono- and di- zygotic twins have been performed. Monozygotic twins shown a 
higher concordance rate for alcoholism and alcoholic cirrhosis compared to di­
zygotic twins (Hrubec and Omenn, 1981). Twin studies also suggest a high degree 
of genetic influence on ethanol elimination rate and susceptibility to alcohol 
intoxication (Kopun and Propping, 1977).
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1.6.2 Gender
The prevalence of alcoholic cirrhosis is higher in males than females, being 
estimated in Scotland at 2.3:1 in 1981 (Hislop, 1981). However, the male: female 
ratio of problem drinking is higher still, being estimated at 5-10, although there has 
been a disproportionate rise recently in alcohol consumption by females 
(Department of Health, 1999). Differences in susceptibility between the sexes are 
also likely to be culturally determined in part
Females are generally considered more susceptible to the pathogenic effects of 
alcohol than males (Naveau et al., 1997). The cirrhotogenic threshold probably 
occurs at a lower alcohol dose in females (Norton et al, 1987). Women appear to 
develop liver disease more rapidly and at the time of presentation their liver disease 
is more advanced than men (Ashley et al, 1977), (Morgan and Sherlock, 1977), 
although this may be partly related to a lower index of suspicion for alcohol- related 
disease in women. As noted earlier, liver disease is more likely to progress 
following abstinence in women (Pares et al, 1986).
Females have a lower body weight and increased percentage body fat resulting in a 
higher peak blood alcohol concentration following ingestion of the same oral 
ethanol dose. There are notable sex differences in hepatic and gastrointestinal 
metabolism of alcohol and in the response to inflammation that may influence
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susceptibility. Auto antibodies are found more frequently in female patients with 
alcoholic liver disease (Krasner et al., 1977b).
1.6.3 Ethnicity
Different ethnic groups have differing susceptibilities to alcohol- related disease. 
This is likely to be due to a combination of genetic, environmental, and cultural 
factors. Alcoholism and alcohol- related disease is less frequent in Oriental 
populations, probably because of differences in acetaldehyde metabolism. African -  
Americans have a higher risk of upper GI tract neoplasia than white Americans after 
standardizing for alcohol and tobacco exposure (Brown et al., 1994).
Alcohol dehydrogenase isoenzyme distribution shows marked ethnic variation, and 
this is discussed in more detail in chapter 2. Native Americans and Eskimos have a 
high prevalence of alcoholism and alcoholic liver disease. Alcoholic hepatitis is 
associated with a higher mortality in Native Americans than Hispanics, Caucasians, 
or African-Americans (Rex et al., 1985). Whilst some studies have suggested an 
increased alcohol metabolic rate in Orientals, Hispanics, Native Americans and 
Eskimos compared to Caucasians, other studies have found little significant 
difference, and stress that the intra- ethnic variability in the alcohol metabolic rate is 
greater than that observed between ethnic groups (Bennion and Li, 1976), (Reed,
1978).
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1.6.4 Genetic studies
Family studies suggest that susceptibility to alcohol related disease is multifactorial, 
being partly environmental and partly polygenic. When considering specific genes 
determining susceptibility to alcohol related injury, the obvious candidates for study 
are those involved in regulation or expression of alcohol metabolising enzymes. 
However, the hereditary component of alcohol related disease suggested by femily 
studies cannot be explained by the known differences in alcohol metabolising genes 
alone (Whitfield, 1997).
The pathological response to alcohol in many organs, particularly the liver, appears 
to be mediated by inflammation, and hence the potential for genetically determined 
differences in the inflammatory response have been explored. The human leukocyte 
antigen (HLA) loci have been recognised for decades, and these were therefore the 
subjects of many early studies on the genetics of alcohol related disease. Early 
reports identified many possible HLA associations with alcoholic liver disease, for 
example, HLAB8, B13 and B40. However, subsequent studies (Mills etal., 1988) 
and meta- analyses have identified no clear association, and it is likely that earlier 
studies were flawed.
Despite the association of alcoholism with iron overload, heterozygosity for the 
haemochromatosis gene does not appear to increase the risk of alcohol- related liver 
damage (Grove et al., 1998).
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Recent advances in genetic techniques have allowed studies that focus on individual 
genes associated with inflammatory cytokines, which will be discussed in more 
detail later in this chapter.
1.7 Alcohol metabolism
Alcohol is both water and lipid soluble and is therefore capable of permeating all 
tissues. The body has no mechanism for storing or partitioning alcohol, and 
therefore any ingested alcohol has to be metabolised or excreted unchanged. The 
acute effects of alcohol on the central nervous system are probably mediated by 
alteration in the fluidity of cell membranes. However, the major site of alcohol 
related damage is in the tissues where alcohol is metabolised, and hence it is 
important to consider how metabolism may cause damage. However, metabolism 
may also have a protective role by limiting the exposure of certain organs to alcohol. 
At concentrations encountered in social drinking, approximately 1% of alcohol is 
eliminated from the body via the lungs, kidneys, and skin without being metabolised 
(Holford, 1987).
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1.7.1 Alcohol dehydrogenase
Alcohol dehydrogenase (ADH) is a zinc- dependent oxido- reductase metallo- 
enzyme that is responsible for the metabolism of the majority (90%) of ethanol 
reaching the systemic circulation at low concentrations in normal subjects. There are 
multiple molecular forms of ADH with differing kinetic properties and distributions. 
This is discussed in more detail in chapter 2. ADH is relatively substrate non­
specific, being able to metabolise a variety of primary and non- primary alcohols 
(including methanol, ethylene glycol and retinol, sterols and aldehydes) (Kim et al., 
1992), (Raskinetal., 1976).
The vast majority of alcohol dehydrogenase (80- 90% of total activity) is present in 
the liver in hepatocyte cytosol. ADH is also found throughout the gastro- intestinal 
tract particularly in the oesophagus and stomach (Pestalozzi et a l, 1983), (Buhler 
and Wartburg, 1982), (Yin et al, 1997). The equation for the metabolism of alcohol 
to acetaldehyde by ADH is shown in Figure 1.1a. Nicotinamide adenine 
dinucleotide (NAD) is required as a cofactor by ADH. The equation for the second 
metabolic step, the metabolism of acetaldehyde to acetate by acetaldehyde 
dehydrogenase, is shown in Figure 1.1b. The metabolism of acetate by the enzymes 
of the citric acid cycle to carbon dioxide and water takes place mainly in the 
peripheral tissues.
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a) CH3-CH2-0H + NAD"^->CH3-CH0 + NADH + H*
Alcohol oxidation by alcohol dehydrogenase
b) CH3-CHO + NAD"" + H2O ^  CH3-COO + NADH + 2KT 
Acetaldehyde oxidation by acetaldehyde dehydrogenase
c) CH3-CH2-OH + NADPH + I t  +2 O2 -> 2 H2O2 + CH3-CHO + NADP^ 
Alcohol oxidation by microsomal ethanol oxidising system (CYP2E1)
d) CH3-CH2-OH + H2 0 2 -> CH3-CHO + 2H2O 
Alcohol oxidation by catalase
e) R-COOH + CH3-CH2-OH -> R-CO-O-CH2-CH3 4- H2O 
Non-oxidative metabolism of alcohol by fatty acid ethyl esterase
Figure 1.1 Chemical equations related to alcohol metabolism
Ethanol: CH3-CH2-OH, Acetaldehyde: CH3-CHO, Acetate: CH3-COO, 
Nicotinamide adenine dinucleotide: NAD\ Nicotinamide adenine dinucleotide 
phosphate: NADP\ Hydrogen peroxide: H2O2, R-COOH: Fatty Acid. (Gillham et 
al., 1997)
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The presence of ADH in the gastrointestinal tract has led to interest in the role of the 
GI tract, and the stomach in particular, in the pre- systemic metabolism of ethanol. 
Alcohol is absorbed poorly by the stomach, and much more rapidly by the jejunum. 
Theoretically, those with high activity of gastric ADH (GADH) may be resistant to 
the effects of alcohol, as a greater amount will be metabolised prior to entry into the 
portal system and thereafter the systemic circulation. The rate of gastric emptying 
will determine the exposure time of GADH to ingested alcohol as well as 
influencing the rate of delivery of absorbed alcohol to the liver. Individuals who 
have undergone gastrectomy show a decreased pre-systemic metabolism of ethanol 
(Caballeria et al., 1989b), (Frezza et al., 1997). The various genetic and 
environmental factors that affect ADH activity are discussed in detail in Chapter 2. 
The contribution of the stomach to the pre-systemic metabolism of alcohol remains 
controversial (Gentry e ta l, 1994a), (Gentry et al, 1994b), (Levitt, 1994a).
Hepatic ADH-dependent alcohol metabolism reaches a maximal rate at low levels of 
alcohol ingestion that are below those encountered in normal social drinking. The 
rate of alcohol elimination in non- alcoholics, which is mainly ADH dependent, is 
approximately 0.1 g ethanol/ kg body weight/ hour (Holford, 1987). The fector 
determining the rate of maximal ADH- dependent ethanol metabolism is the 
availability of NAD, rather than the amount of ADH present. In other words, ADH 
is not fully saturated when the maximal rate is reached. The availability of NAD is 
dependent on the ability of mitochondria to indirectly regenerate NAD from NADH, 
its reduced form, via the electron transport chain, a process that ultimately requires
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oxygen. The rate of alcohol metabolism in healthy individuals is directly related to 
liver cell mass. Some studies have suggested that because adult males and females 
tend to have a liver of the same size, their overall alcohol elimination rates are the 
same. However, when this is expressed as a proportion of lean body mass, females 
have a higher elimination rate as they have a greater liver mass per unit of lean body 
mass (Kwo et al., 1998). However, there is still controversy regarding the sex 
difference in the rate of alcohol metabolism, with others suggesting that the female 
alcohol elimination rate is faster in studies which adjusted the alcohol dose to give 
the same peak blood alcohol concentration as males, and expressing the rate 
independent of body weight (Thomasson et al., 1995).
A modest increase in rate of alcohol elimination by ADH can be achieved by co­
administration of large amounts of fructose (Brown et al., 1972). This probably 
results from an increased rate of re-oxidation of NADH by the products of fructose 
metabolism.
Ingestion of large quantities of alcohol decreases the ratio of NAD: NADH and 
pyruvate: lactate, the so- called “redox state” of the liver, which profoundly affects 
the other metabolic functions of the liver. Gluconeogenesis is reduced which may 
cause hypoglycaemia. Substrate utilization by the Krebs’ cycle and beta- oxidation 
and export of fetty acids is reduced, leading to triglyceride accumulation and fatty 
liver. Higher oestrogen levels in females also have an inhibitory effect on beta- 
oxidation of fatty acids, which may partly account for their accelerated development 
of alcoholic fatty liver.
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The rate of hepatic clearance of some drugs by pathways that are also dependent on 
NAD (e.g. glucuronidation) is reduced (Lieber, 1994). Excess NADH has a pro­
oxidant effect by increasing the synthesis of purines and shifting their metabolism 
from xanthine dehydrogenase to xanthine oxidase (Kato et al., 1990) and by 
promoting the liberation of iron from ferritin.
1.7.2 Hepatic hypermetabolism
Following acute alcohol ingestion, it is estimated that approximately 40% of liver 
oxygen consumption in the non- alcoholic is used in the metabolism of ethanol to 
acetate (Greenway and Lautt, 1990). After chronic alcohol administration, the 
oxygen demand of the liver rises (Souda et al., 1996), probably as a result of enzyme 
induction. There is a rise in liver blood flow, mainly due to increased portal vein 
flow, after alcohol administration, both intravenously (Mendelhoff, 1954), (Silva et 
al., 1994) and orally (Piano et al., 1991), (Kogire et al., 1992), (Orrego and 
Carmichael, 1992). This increased blood flow may not be sufficient to meet the 
oxygen demands of the liver following chronic ethanol consumption (Fukui et al., 
1990), and is shunted away from the liver by collaterals when cirrhosis is present 
(Luca et al, 1997). Liver blood flow falls rapidly on alcohol withdrawal, whilst 
hepatic oxygen demand remains elevated for approximately 30 days thereafter 
(Israel and Orrego, 1984).
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The liver lobule is perfused from the portal vein and hepatic artery branches in the 
portal tracts towards the central venules, with the lowest oxygen tension therefore 
arising in the perivenular areas (zone 3). This is the area of most prominent liver 
damage in alcoholic liver disease. Hence, alcoholics may be prone to ischaemic liver 
injury (Kasahara et al., 1988), especially in situations that further decrease hepatic 
oxygen delivery, e.g. anaemia, acute alcohol withdrawal (Hadengue et al., 1988), 
(Hadengue et al., 1994), and hypotension.
1.7.3 Acetaldehyde
Acetaldehyde, the first product of alcohol metabolism, is highly reactive and 
consequently can promote damage by bonding with other molecules. Hepatic 
acetaldehyde dehydrogenase (ALDH), metabolises over 90% of acetaldehyde. It has 
multiple molecular forms, of which the Class 1 and 2 isoenzymes, coded for by 
ALDHl and ALDH2 loci respectively, are involved to a significant extent in 
acetaldehyde oxidation. ALDH2 is located in mitochondria. It has a relatively low 
Michaelis constant (Km) (i.e. a high substrate affinity) and a high maximum reaction 
velocity (Vmax), and is responsible for the vast majority of hepatic acetaldehyde 
metabolism (Boston et al., 1993). Under normal circumstances, significant 
concentrations of acetaldehyde can only be found in the liver and colon. In 
alcoholics, higher levels of acetaldehyde are detectable in the blood after alcohol 
ingestion than in non- alcoholics (Peterson and Polizzi, 1987). This is probably as a
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consequence of hepatocyte and mitochondrial damage because levels return to 
normal on re-administering alcohol after a prolonged period of abstinence (Di 
Padova et al, 1987b).
Bonding of acetaldehyde with protein results in the formation of acetaldehyde- 
protein adducts (for example with microsomal proteins, collagen, albumin, 
haemoglobin, lipoproteins, and the tubulin of microtubules (reviewed by (Lieber, 
1994)). These adducts may alter the biological function of proteins, or may impair 
protein excretion. Impaired excretion may account for the ballooning of hepatocytes 
observed histologically, as this is associated with increased hepatocyte protein 
content (Tuma and Sorrell, 1988). These adducts are also antigenic. Antibodies 
directed against adducts are found in the blood of alcoholic patients (Niemela et al, 
1987). Inoculation of ethanol fed animals with sera from humans with alcoholic 
cirrhosis causes hepatocyte cytotoxicity mediated by antibodies to acetaldehyde- 
protein adducts (Clot et al, 1997), (Israel, 1997).
Acetaldehyde that is not metabolised by ALDH can be converted to acetate by 
xanthine oxidase. This will promote free- radical mediated peroxidation of lipids 
that can also occur from acetaldehyde directly.
The mitochondria are likely to be particularly susceptible to damage as they are a 
major site of acetaldehyde metabolism and therefore a target for direct or free 
radical induced peroxidation of lipids, protein, and DNA. Mitochondrial DNA is 
more sensitive to damage as it lacks the protection of histone and non- histone
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proteins associated with nuclear DNA, and it has a relatively limited ability for self­
repair.
High blood concentrations of acetaldehyde (higher than those usually observed in 
chronic alcoholics) may occur following acute alcohol ingestion because of low 
ALDH activity. This has been termed the acute aldehyde syndrome. This high 
acetaldehyde level produces aversive symptoms clinically, with flushing, nausea, 
vomiting, and dizziness. The unpleasant nature of these symptoms forms the 
rationale for the use of disulfiram, an acetaldehyde inhibitor often prescribed in an 
attempt to enforce abstinence. Polymorphisms of the mitochondrial form of ALDH 
are recognised. The common allele in Western populations is ALDH 2*1, with the 
common genotype denoted 2*1/2*1. The 2*2 polymorphism results in very low 
mitochondrial ALDH activity. Populations of Mongoloid descent (Chinese, 
Japanese, Taiwanese, etc) commonly have the 2*2 allele, with approximately 50% 
having reduced ALDH activity. Those who are 2*2 homozygous, with almost no 
mitochondrial ALDH activity, experience the symptoms of acute aldehism after 
alcohol ingestion. Alcoholism is therefore much less common in Oriental 
populations. Heterozygosity (i.e. ALDH 2* 1/2*2) is associated with a higher 
incidence of damage in alcohol metabolising organs (Agarwal, 1997), and this is 
probably because of higher acetaldehyde levels than in 2*1 homozygotes, but a less 
marked flushing response than in 2*2 homozygotes.
There is a relative imbalance in the activities of alcohol and acetaldehyde 
dehydrogenase (ALDH) in the oesophagus, and to a lesser extent the colon, with a
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higher relative activity of alcohol dehydrogenase (Yin et al., 1997). This will favour 
increased local production of acetaldehyde, and is one proposed mechanism by 
which alcohol may predispose to malignancy at these sites.
Many gastro- intestinal bacteria, including HP (Kaihovaara et al., 1994), contain 
alcohol dehydrogenase. In the presence of alcohol, either from ingestion into the 
upper GI tract, or by back diffusion of absorbed alcohol into the lumen, these 
bacteria may produce acetaldehyde. These may cause local tissue damage or 
promote carcinogenesis, especially in areas of relatively low ALDH activity (Seitz et 
al., 1990). An association with the ALDH 2*2 allele and oesophageal carcinoma has 
been described (Hori e ta l, 1997), (also reviewed by (Agarwal, 1997)). The 
bacterio-coIonic pathway for ethanol oxidation may also account in part for the lost 
calories associated with a diet high in alcohol. Higher acetaldehyde levels have been 
found in the colon than in the liver after acute alcohol ingestion (Jokelainen et al,
1996).
1.7.4 Microsomal ethanol metabolism
The second major pathway of hepatic ethanol metabolism is via the cytochrome- 
dependent microsomal ethanol oxidising system, in particular the cytochrome p450 
2E1 (CYP2E1) enzyme sub-Auction (Lasker et al, 1987), but also to a lesser extent 
the CYP1A2 and CYP3A4 fractions (Figure 1.1c). These are a series of low- 
specificity oxidases found in the endoplasmic reticulum that are largely involved in
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metabolism of drugs and other foreign substances (xenobiotics). They are inducible 
on chronic exposure to substrates including alcohol, some drugs (particularly 
anticonvulsants), and polyunsaturated fatty acids (Wade et al., 1985). In chronic 
alcoholics, they account for the increased rate of alcohol metabolism that is 
frequently observed. They may account for up to 50% of the metabolism of ethanol 
in chronic alcoholics, but usually contribute less than 10% in moderate drinkers who 
are not taking other medications causing enzyme induction. They contribute most to 
alcohol metabolism at high blood levels, because they have a higher than ADH. 
They require NADPH rather than NAD as a cofactor, and generate hydrogen 
peroxide (H2O2) along with acetaldehyde, with the formation of free radical 
intermediaries (via the Fenton reaction). ATP is not generated by alcohol oxidation 
by this route, and hence this form of metabolism is energy wasting and will 
contribute to the lost calories of diets high in alcohol.
Induction of microsomal enzymes by ethanol may lead to a shift in metabolism of 
other substrates, particularly xenobiotics, resulting in increased production of 
atypical and often toxic metabolites by microsomal oxidation. The clearest example 
of this is the increased susceptibility of alcoholics to paracetamol toxicity. 
Paracetamol is normally metabolised by glucuronidation or sulphation and is then 
excreted by the kidneys. In the presence of high paracetamol levels, (e.g. following 
overdose) it undergoes cytochrome- dependent oxidation to N-acetyl-benzo- 
quinone-imine. This precipitates hepatocyte death by inducing free radical damage 
and covalent bonding to structural proteins unless a glutathione- dependent
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metabolic pathway inactivates it. The toxic threshold of paracetamol is reduced in 
alcoholics because of the induction of microsomal enzymes.
The period immediately following alcohol withdrawal after chronic drinking may be 
a particularly sensitive time for damage from xenobiotic metabolism, because the 
microsomal enzymes will not be saturated with ethanol, but remain induced and 
therefore have a higher activity.
Further evidence that the microsomal enzymes contribute significantly to alcohol- 
mediated damage comes from the observation of the pattern of injury in alcoholic 
liver disease, and studies of CYP2E1 inhibitors. As discussed earlier, the majority of 
damage occurs in zone 3, which is particularly prone to hypoxia. This is also the site 
where the CYP2E1 enzymes are located. Animal studies have shown increased 
acetaldehyde adduct formation in zone 3, and studies using CYP2E1 inhibitors 
(Morimoto et al., 1995) have shown attenuation of alcoholic liver injury in zone 3.
1.7.5 Other forms of alcohol metabolism
Alcohol can also be metabolised by catalase in the presence of hydrogen peroxide 
(Figure l.ld). However, under physiological conditions catalase appears to play no 
major role in ethanol metabolism.
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After acute alcohol ingestion the concentration of fatty acid ethyl esters (FAEE), 
formed by non- oxidative metabolism (Figure l.le), rises in the pancreas, liver, heart 
and adipose tissue (Laposata and Lange, 1986). Adipose tissue has the highest 
concentration of FAEE, followed by the pancreas. The activity of fatty acid ethyl 
esterase is much higher, and the activity of ADH much lower, in the pancreas 
compared to the liver. In animal studies, FAEE activate inflammation and collagen 
deposition in vitro (Lugea et al., 2001). Non- oxidative alcohol metabolism may 
therefore be more important than oxidative metabolism in the causation of alcoholic 
pancreatitis.
1.8 Oxidative stress and antioxidant defences
As discussed earlier, alcohol metabolism promotes oxidative damage by a variety of 
means. Increased NADH and acetaldehyde increases xanthine oxidase activity with 
the production of superoxide (Of ). Acetaldehyde can form peroxides directly. 
Induction of cytochrome dependent enzymes leads to free radical intermediaries, 
and the generation of hydrogen peroxide. Hydrogen peroxide may react to form 
further free radicals, or may be removed by glutathione peroxidase, which consumes 
hepatic reduced glutathione.
Increased oxidative stress results in membrane damage with loss of structure and 
function, and DNA damage that can cause mutagenesis, loss of function, and cell 
death. Free radical oxidation of protein results in similar effects to those described
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for acetaldehyde- protein adducts. An increase in free radical generation will also 
lead to depletion of intra-hepatic antioxidant defences. Alcoholics have reduced 
levels of hepatic glutathione, and increased levels of molecules derived from lipid 
peroxidation (Clot et al., 1994). There is evidence of diminished levels of vitamins 
A, C (Beattie and Sherlock, 1976), E, and selenium, in alcoholic liver disease 
(reviewed by (Lieber, 1994)). Antioxidant depletion is exacerbated by malnutrition. 
In animal studies, dietary deficiency of antioxidant micronutrients is associated with 
increased hepatic lipid peroxidation (Kawase et al., 1989). Chronic alcoholism also 
increases the liberation of iron from ferritin and promotes hepatocyte iron uptake.
A polymorphism of the superoxide dismutase gene has recently been described in 
association with an increased incidence of hepatic lesions, although the functional 
significance of this polymorphism is not known at present (Degoul et al., 2001).
1.9 Glutathione and phosphatidylcholine
Glutathione can be synthesised from cysteine, which in turn can be synthesised from 
methionine, an essential amino acid. Alcoholics appear to have impaired methionine 
utilization, with depletion of the active methionine metabolite S- adenosyl 
methionine (SAM) due to impaired SAM synthetase activity. SAM is also required 
for transmethylation reactions and production of phosphatidylcholine from 
phosphatidylethanolamine. Depletion of SAM may therefore affect DNA synthesis 
and membrane lipid constituents of the cell and mitochondrion. A study of SAM
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supplementation has shown a promising reduction in mortality in alcoholics with 
Child’s group A and B cirrhosis (Mato et al, 2000).
Alcoholism decreases liver phospholipid and phosphatidylcholine. An additional 
acquired enzyme defect of phospholipid methyltransferase means that synthesis of 
phosphatidylcholine may still be impaired in alcoholics following SAM 
supplementation. Phosphatidylcholine supplementation corrects the hepatic deficit 
and protects against fibrosis and cirrhosis in the alcoholic baboon model (Lieber et 
a l, 1994).
1.10 Hepatic inflammation and endotoxin mediated injury
In contrast to the proposed barrier role of the stomach to the effects of alcohol on the 
liver and systemic organs, the lower GI tract may provide the stimulus for hepatic 
inflammation in susceptible alcoholics. Translocation of colonic bacteria may be 
responsible for initiating or perpetuating the inflammatory response in alcoholic 
hepatitis. Increased intestinal permeability to macromolecules and increased 
circulating levels of endotoxin have been demonstrated in alcoholics, with 
correlation between the severity of liver disease and the degree of increased 
permeability (Parlesak et al, 2000). In animal models, inoculation of gut derived 
endotoxin (lipopolysaccharide, (LPS)) augments alcohol induced liver injury, and 
gut sterilization decreases alcohol induced hepatic damage (Enomoto et al, 2001). 
The inflammatory effects of LPS appear to be mediated by Kupffer cells that are
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activated via the LPS receptor (CD 14). Chronic alcohol exposure increases the 
sensitivity of Kupffer cells to LPS (Enomoto et al., 2001). Activated Kupffer cells 
induce further inflammation by secretion of inflammatory mediators. Tumour 
necrosis factor alpha (TNF alpha) appears to be of major importance in promoting 
hepatic inflammation. The severity of hepatic inflammation correlates with levels of 
pro-inflammatory cytokine such as TNF alpha and interleukin 1. In animal models, 
females appear more susceptible than males to alcohol and LPS mediated hepatic 
injury. This may be because of more pronounced sensitisation of Kupffer cells by 
alcohol in females, or because of a greater increase in intestinal permeability (limuro 
etal., 1997).
Several genetic polymorphisms associated with cytokines that regulate the 
inflammatory response have been identified. A rationale for the association of these 
polymorphisms with alcoholic liver disease can be proposed in some cases where 
the functional significance of the polymorphisms is understood, and the associated 
polymorphism will tend to exaggerate the inflammatory response. This is the case 
with the interleukin-10 (IL-10) 627* A polymorphism which is associated wilh 
decreased IL-10 expression. It will favour an increased inflammatory response, and 
is found more frequently in alcoholics with severe liver disease than those with mild 
or no liver disease (Grove et al., 2000). However, in other cases the functional 
significance of certain polymorphisms associated with alcoholic liver disease is less 
well understood, for example the TNF alpha promoter polymorphism G-283A, was
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identified in one study to be more common in alcoholic steatohepatitis (Grove et al.,
1997), although its functional significance is controversial (Bayley et al, 2001).
1.11 Mechanisms and markers of alcohol- induced fibrosis
The cirrhotic liver contains approximately six times the amount of collagen (mainly 
types I and HI) of normal liver (Rojkind and Martinez-Palomo, 1976). Extracellular 
matrix (ECM) was formerly considered almost inactive metabolically, and apart 
from some isolated reports (Perez-Tamayo, 1979), fibrosis was previously thought 
to be irreversible. Fibrosis is now recognised to be a dynamic process, involving an 
imbalance between the ongoing processes of ECM synthesis and degradation, and is 
now considered at least partly reversible, particularly for hepatic fibrosis of non­
alcoholic aetiology.
The fundamentally important cell in hepatic fibrosis is the hepatic stellate cell (HSC) 
(also known as the Ito cell or hepatic lipocyte), which is normally present in the 
space of Disse. The quiescent HSC can become activated by a number of stimuli, in 
particular transforming growth factor beta (derived from Kupffer cells and also from 
HSC themselves), but also other inflammatory cytokines, absence of normal ECM, 
and other factors that are yet to be characterised fully. Activated HSC proliferate and
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undergo change, with loss of retinyl ester stores, and assume a myofibroblast 
phenotype, secreting both collagenous and non-collagenous ECM.
A family of zinc- containing proteinases termed matrix metalloproteinases (MMP) 
degrades ECM proteins. There are 3 broad groups of MMP with differing substrate 
specificities: collagenases, gelatinases and stromelysins. Interstitial collagenase, also 
called M MPl, degrades fibrillar collagen. The activity of the MMP are regulated in 
part by endogenous inhibitors, termed tissue inhibitor of metalloproteinases (TIMP), 
of which there are four types identified at present. HSC secrete MMP 1-3, TIMPl 
and TIMP2 (Iredale et al, 1992) and are hence capable of synthesising, degrading 
and inhibiting the degradation of matrix.
The activity of hepatic collagenase decreases as hepatic fibrosis increases in severity 
(Maruyama et a l, 1982). Fibrotic human liver has increased TIMPl, TIMP2, and 
MMP2 mRNA compared with normal liver (Benyon et al, 1996). MMPl mRNA 
does not increase significantly in fibrosis (Milani et al, 1994). These findings 
suggest that inhibition of collagen degradation is the major factor in determining the 
net collagen increase in hepatic fibrosis. Hepatic fibrosis correlates well with hepatic 
and plasma levels of TIMPl in a range of liver diseases (Murawaki et al, 1997).
Animal studies of experimentally induced fibrosis have suggested that HSC 
apoptosis may be the key event in regression of fibrosis after removal of the toxic 
insult (Iredale et al, 1998).
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The gold standard at present for the assessment of hepatic fibrosis is liver biopsy. A 
serum marker of fibrosis would, however, avoid the risks and morbidity associated 
with this procedure, and may provide information about the mechanisms of 
fibrogenesis in addition to the “snapshot” of fibrosis provided by biopsy. Markers 
that have been evaluated in alcoholic liver disease include collagen precursor 
molecules, such as aminoterminal procollagen m  peptide (PUINP) (Rohde et al,
1979), molecules derived fi'om synthesised matrix, e.g. type IV collagen and laminin 
(Hirayama et al, 1996), (Tsutsumi et a l, 1996), and ECM regulatory molecules, e.g. 
MMP and TIMPl (Benyon et al, 1996), (Murawaki et al, 1997). The collagen 
precursor molecules (e.g. PIUNP) tend to reflect fibrogenesis rather than the extent 
of fibrosis (Rojkind, 1984). Markers derived from matrix (e.g. 7S component of type 
IV collagen) tend to reflect the extent of fibrosis as they are derived from established 
rather than new ECM (Hirayama et al, 1996). Levels of all markers tend to be 
higher in alcoholic rather than non- alcoholic liver disease (Hirayama et al, 1996), 
and tend to M  several weeks after cessation of alcohol consumption (Tsutsumi et 
a l, 1996). Factors other than fibrosis, e.g. changes in hepatic blood flow, may affect 
marker levels (Smedsrod, 1988).
The markers described tend to correlate weakly but significantly with hepatic 
fibrosis, limiting their usefulness in standard clinical practice (Chossegros, 1995). 
Direct comparison of markers suggests that type IV collagen may be slightly 
superior in differentiating the degree of hepatic fibrosis (Tsutsumi et a l, 1996).
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However, the precursor and regulatory molecules may he more useful in studies 
concerned with mechanisms of increased fibrosis in response to specific stimuli.
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Chapter 2: Characteristics of alcohol dehydrogenase
2.1 Introduction
Alcohol dehydrogenase (ADH) is found in almost all living organisms and is the 
major enzyme of alcohol metabolism in mammals, including humans. ADH is 
composed of a complex family of enzymes of different classes, with differing 
distributions, substrate preferences, and enzyme kinetics. Although ethanol is often 
the most abundant alcohol available for metabolism, it is very unlikely that it is the 
intended natural substrate for all the ADH family. It is improbable that many 
different ADH genes would be retained over millions of years solely to protect 
against ethanol- related risks (Lands, 1998). The ingestion of ethanol may therefore 
divert ADH subtypes from reacting with their customary physiological substrates. 
This chapter outlines some of the characteristics of ADH, with emphasis on aspects 
which may determine susceptibility to alcohol related disease or alcoholism. I will 
also discuss briefly the various methods of identifying and assaying ADH 
experimentally.
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2.2 Nomenclature
The diversity of ADH enzymes arises from ancient gene duplication followed by 
successive functional mutations. A nomenclature based on class, isozyme and 
allelozyme, which takes account of this diversity, is now recommended. Human 
ADH is a dimeric, zinc- containing métallo enzyme with subunits of mass of 
approximately 40KDaltons. Both homo- and heterodimeric combinations are 
possible but by definition, functional dimers must arise from within the same class 
(Jomvall and Hoog, 1995). The grouping of protein subunits by class is shown in 
Table 2.1. For example, the dimers a a ,  cr<3, a|3i, P1P2, pifz, are possible
functional combinations, whereas a a ,  TTpi, Xp2, are not Substrate and 
inhibitor kinetics differ more markedly between different classes than between 
isozymes. There is a greater degree of amino acid homology between isozymes 
(around 90%) than between classes (around 40%). These differences are due to 
differing lengths of time of genetic divergence, with isozymes having diverged more 
recently than classes. This is summarized graphically in Figure 2.1.
The nomenclature of ADH can be confusing. The terms class and isozyme have, on 
occasion, been used interchangeably. ADH classes and genes have been named 
numerically in order of discovery, resulting in a non- consecutive ordering of genes 
and their products as a consequence of discovery of genes and their associated 
proteins at different times. To improve clarity of nomenclature, renumbering of 
some of the ADH genes has been suggested (Jornvall and Hoog, 1995).
Figure 2.1 Phylogeny of alcohol dehydrogenase
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2.3 Class characteristics of alcohol dehydrogenase
These are outlined in Table 2.1. Class I ADH is abundant in the liver and 
quantitatively has the greatest contribution to hepatic ADH metabolism. It is 
considered the “classical” human ADH. The y  subunits may also be important in
gastric alcohol metabolism, and the metabolism of 3p & 17 p hydroxysteroids.
Orientals metabolise alcohol faster than Caucasians, and this is likely to be due 
to the higher prevalence of the higher activity ADH 2*2 allele in oriental 
populations.
The class II subunit was originally denoted n for “pyrazole resistance” as it was 
found to be relatively insensitive to pyrazole inhibition compared to class I. 
However, it is still more sensitive to pyrazole than class HI ADH. It has not been 
identified outside the liver. Its endogenous substrates may be steroids and bile 
acids.
Class in  ADH is now recognized as the same enzyme as glutathione- dependent 
formaldehyde dehydrogenase. An enzyme similar to Class HI ADH is present in 
almost all species, including prokaryotes. Vertebrate class HI ADH shows a 
remarkable degree of structural consistency between species. It is considered the 
“ancestral” ADH. It is unsaturatable by ethanol, and its primary function is 
probably unrelated to metabolism of ethanol, to which it contributes little 
quantitatively. It is the only ADH found in brain, testis, and placenta. It can
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metabolise retinol (as can class IV ADH) (Kim et al., 1992), and leukotriene 
derivatives.
Class IV ADH (subunit originally denoted a  for “stomach”, or |Ll) is found only
in the upper GI tract. It has the highest activity for ethanol metabolism of any 
ADH class, and does not display substrate inhibition at high ethanol 
concentrations (Stone et al., 1993). This may be important in ethanol metabolism 
by the stomach as the gastric luminal ethanol concentration which is easily 
achievable during social alcohol consumption (around 0.5- IM) is much higher 
than that found in the liver. The absence of this enzyme in 70% of Orientals may 
account for their overall lower gastric ADH metabolism of ethanol, particularly
as y ADH shows substrate inhibition.
2.4 The role of alcohol dehydrogenase as a determinant of alcoholism 
and alcohol related disease
The rate of alcohol elimination can vary as much as 2- 3 fold between 
individuals. It has been estimated that 50% of the variability in alcohol 
metabolism is genetically determined (Bosron et al., 1993), and that 
polymorphisms of ADH may account for a substantial proportion of this. 
However, as discussed in Chapter 1, the availability of reduced NAD is a major 
limiting factor in the overall alcohol metabolic rate at reasonable alcohol 
concentrations. In theory, we might expect higher activity ADH allelozymes to 
increase the rate of acetaldehyde generation, and therefore be associated with
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lower rates of alcoholism due to the aversive nature of acetaldehyde, particularly 
in individuals who have the mutant inactive polymorphism for acetaldehyde 
dehydrogenase, ALDH2*2 (discussed in chapter 1). However, we might also 
expect those with high activity ADH allelozymes who become alcoholics to be 
more prone to acetaldehyde- mediated damage, although this might be offset by 
a lessening of damage due to alcohol directly, as this is metabolised faster.
The association of Class IP  and y allelozymes and alcoholism and alcoholic
liver disease has been studied extensively. A meta- analysis of these studies 
(Whitfield, 1997) confirms the theoretical expectations, with the lower activity 
ADH2*1 allele associated with an increased risk of alcoholism (common odds 
ratio 2.8). There is a progressive increase in risk fi-om lower risk ADH2*2 
homozygotes, medium risk ADH2* 1/2*2 heterozygotes, to higher risk ADH2*1 
homozygotes. These positive findings have only been observed in Oriental 
populations, although the low fi*equency of the ADH 2*2 allele in Caucasians 
means that studies in this population were underpowered, with wide confidence 
intervals. The ADH 2*1 allele is associated with a reduced tendency to alcoholic 
liver disease in Oriental populations (common odds ratio 0.56), again confirming 
theoretical expectations. The findings are again inconclusive in Caucasians. 
These associations with alcoholic liver disease and alcoholism were not 
conditional on the status of the acetaldehyde dehydrogenase allele.
The higher activity ADH 3*1 polymorphism is associated with a decreased risk 
of alcoholism in Orientals, but not Caucasians. However, this positive finding
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may be related to linkage disequilibrium between the ADH 2*1 and ADH 3*2 
alleles in Orientals.
The ADH 2*3 allele is usually observed only in populations of African decent. It 
was found in 25% of an African- American population, and its presence 
significantly influences the rate of alcohol metabolism, although it is not 
associated with an altered risk of alcoholism (Thomasson et al., 1995).
In contrast to the findings with liver disease, the lower activity ADH 2*1 allele is 
associated with an increased risk of carcinoma of the oesophagus (Hori et al.,
1997). The risk is highest in 2*1 homozygotes, intermediate in heterozygotes, 
and least in 2*2 homozygotes. This risk is independent of, but synergistic with, 
the effect of ALDH allele status, which was discussed in Chapter 1.
2.5 Factors influencing alcohol dehydrogenase activity
Genetic and environmental factors other than variation in class and subclass can 
influence ADH activity.
2.5.1 Age
Gastric ADH activity has been shown by some, but not all, researchers to 
decrease with advancing age (Pozzato et al., 1995), (Moreno et al., 1994),
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(Matsumoto et al., 2001). This was not observed by Yin et al., 1997 in a study of 
subjects of Oriental origin.
2.5.2 Gender and ethnicity
Young and middle- aged females have lower GADH activity compared to males, 
although with advanced age the sex difference tends to diminish (Frezza et al., 
1990), (Seitz et al., 1993), (Baraona et al., 2001).
There have been marked differences in ADH activity observed in different racial 
groups (Dohmen et al., 1996), reflecting the differences in amount of class IV 
ADH, and class I genetic polymorphisms. These ethnic and gender differences 
have been suggested by some (Frezza et al., 1990), (Baraona et al., 2001) 
(Dohmen et al., 1996) to contribute to in lower first pass metabolism, possibly 
causing an increased susceptibility to the effects of alcohol, although this 
remains controversial (Gentry et al., 1994a), (Levitt, 1994a), (Gentry et al., 
1994b).
2.5.3 Alcoholism
The activity of hepatic ADH decreases in alcoholic liver disease (Vidal et al., 
1990), (Panes et al., 1989). This is related to the severity of the underlying liver 
disease, rather than the amount of alcohol consumed, and is therefore likely to be 
a direct consequence of hepatic (in particular mitochondrial) damage. Gastric
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ADH activity is also decreased in alcoholism, most likely as a consequence of 
alcoholic gastritis (Seitz et al., 1993).
2,5.4 Helicobacter pylori
Helicobacter pylori (HP) infection is associated with reduced gastric ADH 
activity (Salmela et al., 1994), (Thuluvath et al., 1994), (Gupta et al., 1994), 
(Simanowski et al., 1998), (Roine et al., 1995), (Kechagias et al., 2001), 
(Matsumoto et al., 2001), despite the presence of a native ADH within HP 
(Kaihovaara et al., 1994), (Salmela et al., 1993). This is likely to be secondary to 
the gastritis that results from infection (Pedrosa et al., 1996), (Brown et al.,
1995). The attenuation in activity is mainly antral, in keeping with the usual 
distribution of HP infection. Eradication of HP is associated with a rise in gastric 
ADH activity (Gupta et al., 1994), (Kechagias et al., 2001), (Simanowski et al.,
1998).
2.5.5 Alcohol dehydrogenase inhibitors
Methylpyrazole is regarded as the classical inhibitor of ADH. It has recently 
been shown to be at least as effective as ethanol in the prevention of 
formaldehyde toxicity resulting from ADH metabolism in methanol poisoning 
(Brent et al., 2001). Imidazole derivatives have long been recognized as 
inhibitors of horse ADH, and certain drugs with substituted imidazole groups.
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such as Cimetidine, can inhibit ADH. Multiple studies have addressed the 
interaction between H2 receptor antagonists and ADH. Cimetidine competitively 
inhibits y and p 2 subunits, and non- competitively inhibits 7t subunits in vitro 
(Stone et al., 1995). Some studies have shown that Cimetidine therapy can 
produce an increase in the peak blood alcohol concentration, the area under the 
curve for blood alcohol concentration versus time, and the total dose of alcohol 
absorbed (Palmer et al., 1991), (Caballeria et al., 1989a), (Hemandez-Munoz et 
al., 1990). The dose of Cimetidine required for inhibition is 100 times greater for 
hepatic than gastric ADH (Caballeria, 1991). An increase in peak blood ethanol 
concentration following Cimetidine is only apparent with oral rather than 
intravenous administration (Hemandez-Munoz et al., 1990), suggesting that the 
effect is on gastric rather than hepatic ADH in vivo. The first pass metabolism of 
alcohol is also influenced by the rate of gastric emptying (Dziekan et al., 1997), 
(Oneta et al., 1998), (Kechagias et al., 1998), (Levitt et al., 1997), (Pedrosa et al.,
1996), which may provide another explanation for the observed effects of H2 
antagonists. Cimetidine does not appear to influence gastric emptying, but the 
increase in blood alcohol level observed with Ranitidine may be related to its 
effect on gastric motility (Amir et al., 1996).
Studies addressing the effects of other H2 antagonists have shown no effect of 
Famotidine (Mallat et al., 1994), (Casini et al., 1994), and conflicting results for 
Ranitidine and Nizatidine (reviewed by (Gugler, 1994), (Frezza et al., 1992), 
(Baraona et al, 1994), and (Caballeria, 1991)). Aspirin has also been shown to 
have a minor inhibitory effect on gastric ADH (Gentry et al., 1999), (Roine et al.
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1990). Proton pump inhibitors do not appear to affect gastric ADH (Battiston et 
al., 1997), (Pozzato et al., 1994), (Roine et al., 1992a).
2.6 Experimental detection of alcohol dehydrogenase
Methods of detection of ADH in tissue extracts can be divided into two broad 
groups depending on whether they detect the presence of ADH protein, or detect 
the enzymatic activity of ADH. Ultraviolet spectrophotometry has been used for 
over 50 years to detect ADH activity (Theorell and Chance, 1951). The 
generation of NADH from NAD by ADH in the presence of ethanol results in a 
change in the NADH absorption peak at 340nm. Although this technique is 
simple, it lacks sensitivity and specificity, particularly for crude tissue 
homogenates, which may contain other NAD- dependent oxido- reductase 
enzymes, which can also generate NADH.
Coupling of the ADH- dependent ethanol oxidation with the reduction of a 
coloured substrate (or product) by NADH can improve sensitivity, but not 
necessarily specificity (for example, nitroblue tétrazolium (Fibla and Gonzalez- 
Duarte, 1993)). The green coloured aldehyde N, N- dimethyl-4- nitrosoaniline 
(NDMA) is a special example of coupling. NDMA is a substrate of ADH, and 
hence the coupling reaction involves the enzymatic action of ADH directly, as 
well as being dependent of NADH generated by oxidation of ethanol (Dunn and 
Bernhard, 1971). It therefore offers advantages in terms of both sensitivity and 
specificity. It has been used to assay ADH activity in serum samples (Skursky et
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al, 1979), (Chrostek and Szmitkowski, 1996), (Chrostek and Szmitkowski, 
1997).
The synthesis of specific anti- ADH antibodies has allowed detection of ADH 
protein, but not activity, facilitating both immunohistochemical (Pestalozzi et al, 
1983) and quantitative analysis (Buhler and Wartburg, 1982) of specimens from 
the liver and GI tract.
Various methods have been used in an attempt to identify the activity of specific 
classes or sub-classes of ADH. Isoelectric focussing has been used to distinguish 
between allelozymes (Yin et al., 1997). Class- specific fluorogenic substrates 
have been identified which ADH can catalyse in the absence of alcohol 
(Wierzchowski et al, 1992). These are useful for identifying differences in 
activities of class I or class II ADH in different groups. However, as their 
reaction kinetics differ markedly from ethanol, they are of little use in assessing 
the overall contributions of individual classes to ADH activity, and their total 
activities differ markedly from total ADH activity assessed by other means 
(Chrostek and Szmitkowski, 1995), (Chrostek et al, 1994), (Chrostek and 
Szmitkowski, 1996), (Chrostek and Szmitkowski, 1997).
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Chapter 3: Pharmacokinetics of alcohol
3.1 Introduction
The pharmacokinetics of alcohol in humans are complex, and in the past have 
often been misunderstood by researchers interested in alcohol metabolism. In 
this chapter, I will review the current understanding of alcohol absorption, 
distribution and elimination, and various pharmacokinetic models that are in use. 
Atypical blood alcohol concentration (BAG) versus time curve, with the phases 
attributable to absorption and distribution, and to elimination, is shown in Figure 
3.1.
3.2 Alcohol elimination
One of the first descriptions of alcohol elimination in humans, by Mellanby in 
1919, suggested that the elimination rate could be considered, for practical 
purposes, to be constant, and independent of BAG (Mellanby, 1919). It is now 
understood that in healthy individuals, alcohol metabolising enzymes begin to 
become saturated at relatively low BAG, which is easily attainable during social 
drinking (around 7- 20 mg/dl, (i.e. 1.5- 4.3 mmol/1)) (Holford, 1987). Therefore, 
as BAG increases, the rate of ethanol elimination will not increase in direct 
proportion. At high BAG, a change in BAG results in little corresponding change 
in the alcohol elimination rate. Displaying this information graphically gives rise 
to what has been described as a “Hockey Stick” appearance of the elimination 
portion of the BAG versus time curve, with a relatively straight line
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Figure 3.1 An ideal blood alcohol concentration versus time curve
The vertical line shows the division of the curve into a phase dependent mainly 
on absorption and distribution, and a phase dependent solely on elimination. The 
horizontal line shows the division of the elimination part of the curve into a 
pseudo-linear phase (where alcohol elimination appears to be almost constant), 
and a curvilinear phase, which typically occurs at blood alcohol concentrations 
of around 1.5- 4.3 mmol/1.
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“pseudoiinear” portion of the B AC versus time curve at higher BAG, and a 
concave- upward “curvilinear” portion at lower concentrations (Figure 3.1). 
Viewed simplistically, this curve would suggest a combination of zero- order 
elimination kinetics at high BAG, and first- order elimination kinetics (like most 
common therapeutic drugs) at lower BAG.
The Michaelis- Menten equation (Appendix A.2, Equation 3) is the classical 
biochemical equation describing the relationship between enzyme activity. If it is 
assumed that all the alcohol eliminating enzymes can be considered as acting as 
a “single” enzyme (which is valid at all but very high BAG), then the Michaelis- 
Menten equation and the equation for the “Hockey Stick” curve should be 
related. This is indeed the case, and integration of the Michaelis- Menten 
equation produces an equation for a line with a “Hockey Stick” appearance 
(Lundquist and Wolthers, 1958) (the integrated form is also given in Appendix 
A.3, Equation 6). This equation has been used by a number of researchers to 
estimate alcohol elimination rate (Amir et al., 1996), (Lin et al., 1976), (Roine et 
al, 1991), (Gentry et al., 1999), (Lim et al., 1993), (Di Padova et al., 1992), 
(Levitt and Levitt, 1994b), (Levitt et al, 1997), (Baraona et al., 2001), and to 
estimate population means for the parameters Km and Vmax (Pieters et a l, 1990), 
(Lundquist and Wolthers, 1958), (Wagner et al, 1989).
A simpler method of estimating the alcohol elimination rate is to measure the 
gradient of the pseudo-linear portion of the BAG versus time curve after the 
absorption and distribution phase is complete, and consider the curvilinear phase 
to be so small as to be inconsequential. The equation for this model (which is
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essentially the same as Mellanby’s original description) of alcohol elimination 
was proposed in 1932 by Widmark, and is still used frequently today, in both 
research (Thomasson et al., 1995) and forensic applications.
However, the inaccuracies in this model has led to suggestions that this equation 
should no longer be used, particularly when trying to estimate the alcohol 
elimination rate of particular populations (Wilkinson, 1980). The inaccuracy due 
to the non- linear portion of the curve may be greater in subjects who have a 
higher saturation threshold, for example, chronic alcoholics who have induction 
of CYP2E1 enzymes.
All of these models of elimination make certain assumptions. They assume that, 
for practical purposes, we can consider alcohol to be eliminated uniformly and 
simultaneously from the body compartment in which it distributes, i.e. we are 
considering the body as a single compartment. In reality, elimination will only 
take place in the body water compartment found within the liver (the 
contribution of hepatic and renal excretion of alcohol is negligible at all but 
highly toxic BAG), but the rapid equilibration of differences in alcohol 
concentration in body water makes violation of this assumption unimportant.
A number of assumptions that are commonly made when dealing with first- 
order elimination kinetics will not apply when considering alcohol. The 
assumption that is perhaps applied wrongly most often is that the total dose of 
alcohol absorbed is proportional to the area under the curve (AUG). In non­
linear kinetic systems, a change in the rate of administration will change the 
AUG, even without a change in dose, whilst a small increase in dose will result
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in a disproportionate rise in AUG. This is illustrated in Figures 3.2 and 3.3, using 
a pharmacokinetic model developed on Microsoft Excel, with Michaelis- Menten 
elimination kinetics. Many researchers have wrongly assumed that AUG and 
total dose absorbed are proportional (Simanowski et al., 1998), (Gabaliéna et al., 
1989b), (Frezza et al., 1990), (Dziekan et al., 1997), (Kechagias et a l, 1998), 
(Oneta et a l, 1998), (Pedrosa et al, 1996), (Mallat et al, 1994), (Pozzato et al, 
1994), (Ammon et al, 1996), (Roine et al, 1990), (Battiston et al, 1997), (Gasini 
et al, 1994). However, the AUG is a good indicator of the duration and extent of 
systemic alcohol exposure, and hence it can still provide useful information 
about the potential for alcohol related damage (Thomasson et al, 1995). The 
total dose of alcohol absorbed will be proportional to the area under the curve of 
elimination rate versus time, rather than the area under the curve of concentration 
versus time, and can thus be estimated by integration of the Michaelis- Menten 
equation (the proof is given in Appendix A4, Equation 7) (Gentry et a l, 1992), 
(Lin et al., 1976).
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Figure 3.2 A sample pharmacokinetic model for alcohol absorption, 
distribution, and elimination- effect of change in gastric emptying.
These graphs illustrate a model o f the delivery o f  alcohol from the stomach to small intestine, and its 
subsequent absorption and elimination. Note the amount o f alcohol in various compartments, rather than the 
concentration o f alcohol, is displayed (to allow visualization o f the 3 compartments on one pair o f axes). In 
this model, there is no gastric lag phase, ingestion is in the form o f a single gastric bolus, and gastric 
emptying and intestinal absorption are first order. Alcohol elimination is by Michaelis- Menten kinetics. For 
simplicity, bioavailability is assumed to be 100%. Distribution is instantaneous in a single body water 
compartment. These graphs illustrate that a doubling o f the rate constant for gastric emptying (lower graph) 
results in a 30% greater peak “alcohol amount in body water”, and a 12% increase in the area under the 
“alcohol amount in body water” versus time curve, despite the overall alcohol dose remaining the same.
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Figure 3.3 A sample pharmacokinetic model for alcohol absorption, 
distribution and elimination- effect of change in alcohol dose.
The pharmacokinetic m odel is described in detail in Figure 3.2. These graphs illustrate that a 
doubling o f  the dose o f  alcohol administered results in a disproportionate increase (alm ost three 
tim es) in the area under the curve o f  “alcohol amount in body water” versus time curve. The rate 
constant for gastric em ptying is the same in both graphs.
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3.3 Alcohol ingestion, absorption and distribution
Prior to the linear phase of alcohol elimination, the processes of ingestion, 
absorption, and distribution will describe the BAC versus time curve. Various 
models have been described to explain this phase of the curve.
3.3.1 Ingestion
Alcohol is often delivered as an oral bolus under experimental conditions, 
although it may more accurately reflect social drinking to describe the ingestion 
of alcohol as a zero- order (continuous rate) process during the period of 
consumption.
3.3.2 Absorption
Various models have been applied to describe alcohol absorption. Although 
some alcohol is absorbed from the stomach (Levitt et al, 1997), this occurs 
slowly relative to absorption fi*om the jejunum. Hence, a model is often used 
which describes separate components for gastric emptying and intestinal 
absorption. The delay in gastric emptying is then usually represented either as a 
lag phase, i.e. a period of time during which no absorption takes place, or as a 
phase described by first order principles, i.e. the rate of delivery of alcohol from 
the stomach is directly related to the concentration of alcohol in the stomach, and
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occurs continuously. However, there is evidence that in the fed state, high 
concentrations of alcohol (16% weight/ volume or higher) may retard gastric 
emptying disproportionately (Roine et al., 1991), and a first order model may 
therefore be overly simplistic. Once alcohol has entered the jejunum, absorption 
is regarded as a first order process, in common with most other ingested 
substances, and is much more rapid than alcohol absorption from the stomach 
(Levitt et al., 1997), (Lim et al., 1993). All of the alcohol reaching the lumen of 
the small intestine is usually absorbed (Lim et al., 1993). Ignoring first pass 
metabolism for the present, it can be seen that the rate of increase in the BAG 
versus time curve, and the magnitude of the peak BAG will therefore increase 
directly with the rate of delivery of alcohol to the small intestine, which, in turn, 
will be dependent on the rate of gastric emptying. This implies that even if 
gastric alcohol dehydrogenase activity (GADH) were negligible, the stomach 
would still have a crucial role in determining BAG (and, given the non- linear 
nature of elimination, also the AUG) solely as result of its function as a reservoir. 
Figure 3.2 illustrates the effect of changes in the rate of gastric emptying.
3.3.3 Distribution
Alcohol is capable of permeating all tissues, and is not stored in specific sites, 
but tends to distribute itself mainly in body water, and hence its volume of 
distribution usually reflects total body water closely. This is approximately 40 
litres for a 70kg man aged 40. In single compartment models, distribution is 
usually assumed to be a rapid and uniform process throughout the body water
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compartment. However, if we are using the declining part of the BAG versus 
time curve to estimate alcohol elimination rate (either by Michaelis- Menten 
kinetics, or Widmark’s method), the part of the curve that immediately follows 
the peak should be avoided, as its gradient is partly determined by distribution 
(and it will hence be steeper), which in reality is not instantaneous.
3.4 Overall bio availability
The amount of an ingested drug reaching the systemic circulation is rarely equal 
to the amount ingested. This may be due to a combination of incomplete 
absorption and hepatic metabolism via the portal circulation, prior to entry of the 
ingested substance into the systemic circulation. Incomplete absorption from the 
GI tract may be related to the ingested substance being metabolised by the GI 
tract, bound in the GI lumen, or having a limited ability to cross the GI mucosa.
When alcohol is administered orally, it is incompletely delivered to the systemic 
circulation (Julkunen et al., 1985), (Di Padova et al., 1987a). Alcohol is not 
bound in the lumen of the GI tract, and it crosses mucosal surfaces readily, 
therefore incomplete systemic delivery is likely to be related to either 
metabolism in GI tract (by GADH) or to hepatic first pass metabolism.
Quantitatively, overall first pass metabolism is defined as the amount of a 
substance administered by the oral route minus the amount of substance reaching 
the systemic circulation. For substances obeying linear pharmacokinetic 
principles, this is proportional to the AUG following IV administration (AUGiv)
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minus AUC following oral administration (AUCo). Bioavailability is expressed 
as a ratio of substance entering the systemic circulation: substance ingested. In 
first order systems this can be calculated from AUCo divided by AUCiv. Overall 
bioavailability can also be derived from F x f, where fraction crossing GI 
tract, and F=hepatic bioavailability. In a system with first order hepatic 
elimination, hepatic bioavailability is usually a constant. However, with zero 
order kinetics, the hepatic bioavailability will rise as the delivery of the ingested 
substance to the liver increases, because of saturation of hepatic metabolism. The 
equation relating hepatic (and overall) bioavailability to portal vein concentration 
is given in Appendix A.5, Equation 10. Hence, if the rate of alcohol absorption 
increases, there will be a rise in overall bioavailability (Levitt and Levitt, 1994b), 
(Holford, 1987), Therefore, we can again appreciate the importance of the 
reservoir function of the stomach. It can influence overall bioavailability 
regardless of the activity of gastric ADH. In addition, a prolonged gastric 
emptying time will increase the exposure of gastric luminal alcohol to GADH.
Some authors have demonstrated the importance of gastric emptying in 
influencing overall bioavailability (although not all have realised that differences 
could be explained from non- linear pharmacokinetics principles alone) (Oneta et 
al., 1998), (Pedrosa et al., 1996), (Amir et al., 1996), (Kechagias et a l, 1998), 
(Dziekan et al, 1997), (Levitt et al, 1997). The bioavailability of alcohol can 
vaiy markedly both within and between individuals, and is strongly influenced 
by the ingestion of solid food. In the fasting state, the bioavailability of alcohol is 
often 90% or greater, whilst in the fed state, this can fall to around 50- 60% (Lin 
et a l, 1976). Despite the strong influence of gastric emptying, many researchers
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have not taken account of it when attempting to assess the contribution of gastric 
ADH to overall bioavailability, Oneta et. al. recently suggested that “knowledge 
of gastric emptying time is a major pre-requisite for the study of first pass 
metabolism of alcohol in humans” (Oneta et al., 1998). Figure 3.4 is a flowchart 
illustrating the complex interactions that determine the systemic bioavailability 
of alcohol.
prolongs 
exposure 
to GADH
Stomach
reservoir
function
alcohol
ingestion
gastric
ADH
decreases
absorption
rate
decreases AUC 
of blood alcohol 
(disproportionately)
decreases 
amount 
in lumen
decreases 
amount reaching 
systemic 
circulation
increases 
hepatic 
first pass 
metabolism
Figure 3.4 Flowchart illustrating the role of the stomach in alcohol first 
pass metabolism
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Chapter 4: Aims of thesis
The principal aim of this thesis is to explore the relationship between alcohol 
metabolism and potential mechanisms of, or susceptibility to, alcohol related 
damage. Two main hypotheses are considered.
The first hypothesis considered is that susceptibility to alcohol- related damage 
may partly be determined by gastric alcohol dehydrogenase (ADH). Gastric 
ADH can metabolise alcohol before it reaches the systemic circulation. Hence, 
subjects with higher levels of gastric ADH may absorb less alcohol, and may 
therefore be less susceptible to the effects of alcohol. However, the clinical 
relevance of gastric ADH remains controversial. Reports have suggested that 
Helicobacter pylori eradication has been associated with a rise in gastric ADH 
activity. This thesis therefore studies ^N\iQi\\QV Helicobacter pylori eradication is 
associated with a significant rise in gastric ADH, and whether this is associated 
with a change in pre- systemic alcohol metabolism. A rise in gastric ADH 
activity associated with an increase in pre- systemic alcohol metabolism would 
support the hypothesis, and might provide a useful basis for further studies that 
could attempt to modify an individual’s alcohol metabolism hy Helicobacter 
pylori eradication. A rise in gastric ADH activity without an associated increase 
in pre- systemic metabolism would suggest that gastric ADH does not play a 
significant role in alcohol metabolism.
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To study the effects o îHelicobacter pylori eradication on gastric ADH activity it 
is necessary to have a robust assay for gastric ADH. The secondary aim of this 
thesis was to develop an assay which would improve upon existing ADH assays, 
in that it would be able to detect reliably the low levels of activity found in 
standard endoscopic gastric biopsies following a minimal degree of tissue 
preparation, and which would use semi- automated, but readily available, 
laboratory equipment where possible. This thesis aims to ensure that the assay 
method is optimised, robust, and validated.
The second hypothesis considered is that abrupt alcohol withdrawal may induce 
hepatic damage. The hypermetabolic response of the liver to chronic alcohol 
excess induces a relative hepatic hypoxia. Abrupt alcohol withdrawal may 
worsen this hypoxia by reducing hepatic blood flow, resulting in ischaemic 
damage. The induction of CYP450 enzymes by chronic alcohol excess may 
result in hepatic damage caused by the metabolic products of these enzymes. 
During alcohol withdrawal, these enzymes remain induced but are no longer 
saturated by alcohol, increasing their ability to cause damage at that time, 
particularly by metabolism of certain drugs. This thesis studies markers of 
hepatic damage (hepatic transaminases) and markers of hepatic fibrogenesis 
(amino-terminal procollagen m  peptide and tissue inhibitor of metalloproteinase 
1) during the period of alcohol withdrawal, to determine if there is evidence for 
hepatic damage during this period.
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SECTION 2 STUDIES ON GASTRIC ALCOHOL DEHYDROGENASE 
AND PRE-SYSTEMIC METABOLISM OF ALCOHOL
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Chapter 5: Development of a sensitive, colorimetric, semi- automated assay 
for alcohol dehydrogenase in endoscopic gastric biopsies.
5.1 Introduction
Alcohol dehydrogenase (ADH) is present throughout the gastro- intestinal (GI) 
tract (Pestalozzi et al., 1983), with a relatively high activity in the stomach 
(Buhler and Wartburg, 1982), (Yin et al., 1997). It may contribute to the first 
pass metabolism of alcohol (Pozzato et al., 1995), (Gentry et al., 1994a), 
(Hemandez-Munoz et al., 1990), (Frezza et al., 1990), (Roine et al., 1990), 
(Haber et al., 1996), (Baraona et al., 2001), and it may be important in 
carcinogenesis in the GI tract (Seitz et al., 1990), (Hori et al., 1997). This 
enzyme is therefore currently the subject of much research interest. Although 
ADH is easily assayed using conventional ultraviolet (UV) spectrophotometry, 
this method is non- specific and it lacks sensitivity for the small amounts of 
ADH found in standard endoscopic biopsies. The standard method of tissue 
preparation, namely homogenisation, can be time consuming, particularly when 
dealing with a large number of samples, and can be a source of analytical 
variability, due to non- uniform homogenisation techniques.
The strongly coloured cyclical aldehyde- like substrate N, N-dimethyl-4- 
nitrosoaniline (NDMA) (Figure 5.1) can be reduced to a colourless form in the 
presence of ADH and an alcoholic substrate (Dunn and Bernhard, 1971).
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Preliminary reports in serum have suggested this may offer advantages in 
sensitivity and specificity over traditional ultraviolet spectrophotometry (Skursky 
et al., 1979), (Chrostek and Szmitkowski, 1996), (Chrostek and Szmitkowski,
1997). In our laboratory, previous workers have successfully assayed 
prostaglandins, leukotrienes, histamine, and cyclic adenosine mono-phosphate in 
gastric biopsies by using an incubation technique, rather than homogenisation 
(Taha et al., 1991).
The aims of this study are threefold. Firstly, to develop, optimise, and validate a 
gastric ADH (GADH) assay with improved sensitivity and specificity by using 
NDMA to detect GADH activity in standard endoscopic gastric biopsy samples. 
Secondly, it is hoped that an increase in sensitivity may allow reliable ADH 
detection in samples prepared by incubation rather than homogenisation. Thirdly, 
by semi- automation using 96-well micro-titre plate technology, it is hoped that a 
large number of biopsies can be rapidly processed.
Page 85
NO
Figure 5.1 Molecular structure of N, N-dimethyl-4-nitrosoaniline
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5.2 Patients, materials, and equipment
5.2.1 Patients
After giving informed consent, one hundred and six subjects undergoing upper 
gastrointestinal endoscopy for investigation of dyspepsia, dysphagia, or weight 
loss had paired gastric biopsies taken using standard endoscopic biopsy forceps 
(Olympus FB3K) from the antrum and body of the stomach for ADH 
determination. Further biopsies were taken from the antrum and body for 
standard histological analysis, and a rapid urease (CLO™) test ïor Helicobacter 
pylori (HP) was taken from the gastric antrum. The biopsy material from fifty of 
these subjects (both males and females) was used to optimise the assay. In some 
cases, biopsy material from different subjects was pooled to minimise individual 
variation. Biopsy material from the remaining fifty- six male Caucasian subjects 
(age 22- 72, median 40) was used to provide a reference range for GADH using 
this assay. The endoscopic diagnoses of the subjects whose biopsies were used to 
provide a reference range are summarised in Table 5.1. Subjects with a 
malignant diagnosis, and those taking any medication within 2 weeks of the 
endoscopy which is suspected of interacting with GADH (including H2 receptor 
antagonists, proton pump inhibitors, aspirin, and other anti- ulcer therapy with 
the exception of simple antacids), were excluded from the study. The hospital 
ethics committee granted ethical approval for this study.
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5.2.2 Materials and equipment
The following reagents were obtained from Sigma- Aldrich Ltd. (Dorset, UK): p 
nicotinamide adenine dinucleotide (NAD); 4-methyl pyrazole (4MP); glutamate 
dehydrogenase; acetaldehyde dehydrogenase; ethyl alcohol (ethanol); n-butanol; 
n-propanol; NDMA; Roswell Park Memorial Institute tissue culture medium, 
number 1640 (RPM I1640), with added L-glutamine (final concentration 3 mM); 
lactate dehydrogenase; alcohol dehydrogenase from baker’s yeast (yeast ADH); 
alcohol dehydrogenase from horse liver. A commercial assay was used to 
determine the protein content of the processed biopsy specimens (Micro protein 
determination, phenol reagent method. Sigma, UK, catalogue no: 690-A), a 
variation of Lowry’s method (Lowry et al., 1951).
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Table 5.1 Endoscopic diagnosis in fifty- six subjects in whom biopsy 
material was used to provide a reference range for gastric alcohol 
dehydrogenase
Diagnosis Number Percentage
Normal Endoscopy 12 21.4
Gastritis 13 23.2
Oesophagitis 13 23.2
Duodenitis 10 17.8
Gastric Ulcer 3 5.4
Duodenal Ulcer 7 12.5
Duodenal scarring 7 12.5
Barrett’s oesophagus 1 1.8
All subjects were being investigated for dyspepsia, dysphagia, or weight loss. 
Note that some subjects have more than one endoscopic diagnosis. The 
Helicobacter pylori status was: 37 positive, 19 negative
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In addition, a suspension of cultured HP was obtained. This was prepared by Dr 
Q Zhang, using the methods described in his PhD thesis (Zhang, 1997). In 
summary, this technique involved primary culture of HP obtained from a gastric 
biopsy on Colombia blood agar plates in a micro-aerobic environment at 3TC.  
The cultured HP were then suspended in phosphate buffered saline (PBS), pH 
7.4, to an approximate concentration of 50 million organisms per millilitre, as 
determined by spectrophotometry (an optical density of 0.45 at 620nm).
Polypropylene cryogenic vials (volume: two millilitres) were used to store 
gastric biopsies whilst frozen, and polystyrene twenty-four well tissue culture 
cluster plates were used for incubation of the gastric biopsies (both obtained 
from Coming Costar Corp., Cambridge, Massachusetts, USA). Polystyrene 
ninety- six well microtitre plates (Iwaki brand) were obtained from Asahi 
Techno Glass Inc, Japan.
The ninety- six well plates were read using a Dynatech MR5000 automated 
microtitre plate reader, with 450nm and 620nm filters (Dynatech Labs Ltd., 
Billinghurst, West Sussex, UK). The plate reader was linked to a personal 
computer to allow computerised data collection and analysis using software 
prepared by the author for Microsoft Excel version 9.0 (Microsoft Corp., Seattle, 
Washington, USA).
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A Beckman DU-70 spectrophotometer was used for conventional UV 
spectrophotometry (Beckman Coulter Ltd., High Wycombe, Buckinghamshire, 
UK).
5.3 Methods
5.3.1 Final assay method
The following paragraphs describe the optimised method for the ADH assay.
The incubation times, substrate concentrations, pH, etc. were varied during the 
optimisation experiments that are described in detail in section 5.3.2. Values 
close to the optimum concentration were chosen in each case for the final assay 
except for ethanol and pH. An ethanol concentration of 750mM ethanol was 
chosen because this is within the range of the intra-gastric concentrations of 
alcohol found in social alcohol drinking. A pH value of 7.4 was chosen to refiect 
gastric mucosal cell cytosolic pH.
Immediately after they were obtained at endoscopy, gastric mucosal biopsies 
used for the determination of GADH were placed individually into empty 
cryogenic vials and firozen in liquid nitrogen. These were transferred to a freezer 
for storage at -70° C within 3 hours of being obtained. Biopsies were defrosted 
when required for batch processing and then weighed prior to incubation or 
homogenisation.
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The biopsies that were incubated were placed in covered tissue culture plates for 
24 hours in lOOOul of RPMI 1640 in an atmosphere of 5% carbon dioxide, 75% 
nitrogen and 20% oxygen at 37®C. The cell culture fluid was then retrieved and 
used for further analysis.
A stock solution of NDMA 20mM was prepared in phosphate buffered saline 
(PBS) (pH 7.4). This solution remained stable for several weeks when sealed and 
stored in darkness at 3°C. Phosphate buffered saline (pH 7.4) was used to 
dissolve the contents of a fresh lOmg pre-weighed vial of NAD, which was then 
mixed with the stock NDMA. Two hundred microlitres of this solution was 
added to each well of the 96- well microtitre plate, containing 5 Oui of the biopsy 
homogenate or incubation fluid. After five minutes, the reaction was started with 
the addition of ethanol, to give a final volume of267ul.The final concentrations 
were: NAD (187uM), NDMA (lOOuM), and ethanol (750mM).
Samples were analysed in duplicate in adjacent columns, and duplicates were 
paired with matched duplicate samples containing the ADH inhibitor 4MP 
(18.7mM). The 4MP concentration was optimised so that it inhibited any 
significant reaction observed with the biopsy samples. A sample layout of the 
96- well plate is shown in Figure 5.2. Analysis was carried out at 20^C.
The absorbance of each well at 450nm was measured, using a reference value at 
620nm. Readings were taken at the following times: -5, -3, -1, 0 ,1 ,2 , 3,4, 5, 7, 
10, 15, 20, 30, and 40 minutes. GADH activity was calculated using a kinetic 
plot of absorbance change vs. time determining activity from the initial linear 
portion (Figure 5.3).
Page 92
1 2 3 4 5 6 7 8 9 10 11 12
A
N D M A
standard
90m 90m  +  
4M P
92m 92m  +  4M P 94m
B
N D M A
standard/2 1
90n
1
90n +  
4M P
t
92n
1
I
92n +  
4M P 1
94n
1
C
N D M A
standard/4 1
90o
1
90o  +  
4M P
92o
9 2 o  +  
4M P 1
94o
1
D
N D M A
standard/8
s.
1
90p %
1
90p +  
4M P
%
1
92p s.
1
92p +  
4M P
s.
1
94p s,
1
E
N D M A
standard/16 1
91m
1
91m  +  
4M P 1
93m
93m  +  
4M P
94m  +  
4M P
N D M A OQ 91n 91n +
OQ
93n
OQ 93n + CfQ 94n + OQ
F standard/32 1 o 4M P 1 1 4M P S 4M P
N D M A I
91o I 91o  + 1 93o 1 93o  + I 94o  + 1G standard/64 4M P 4M P 4M P
H
N D M A  
standard/128
91p
91p +  
4M P 93p
93p +  
4M P
94p +  
4M P
Figure 5.2 Sample layout of a 96-well microtitre plate
The 96-well plate has 12 columns (1-12) and eight rows (A-H). This figure 
illustrates the layout for a typical plate. The first 2 rows contain serial dilutions 
of NDMA (highest concentration 150uM), of the same volume as the reaction 
mixture. Five subjects (numbers 90-94) each had 4 biopsies taken (denoted m-p). 
Each biopsy is run in duplicate (for the first 4 samples, these are in adjacent 
columns), and each “active” duplicate pair are run against a “blank” duplicate 
pair which contain the same reaction mixture as the active wells, but in addition 
contain 4-methylpyrazole (4MP), the ADH inhibitor.
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Figure 5.3 Calculation of gastric alcohol dehydrogenase activity from 
gradient of initial absorbance change versus time
This graph illustrates how enzyme activity was estimated from the gradient of 
the initial linear portion of the curve. In this example, the enzyme activity 
decreases after 10 minutes, probably because of depletion of substrate and 
accumulation of product. This example also illustrates that there is no 
appreciable enzyme activity prior to the addition of substrate at time zero.
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Visual verification of the linearity of the initial portion of the curve was 
determined for every sample by inspection of graphs generated using Microsoft 
Excel. Protein concentration of the homogenate or incubation fluid was 
determined using the commercial assay, which was performed by Mr A Fletcher 
(Department of Human Nutrition, University of Glasgow).
The equation relating gradient (i.e. change in absorbance overtime, AA/AT) to 
enzyme activity is derived from the Beer- Lambert law, A=S'C’l, where A=
absorbance, S= molar absorptivity coefficient, C = concentration, and 1= path
length. The published molar absorptivity coefficient of NDMA is 35400M'^cm‘  ^
at 440nm. By analysing serial dilutions of known concentration of NDMA in our
96- well plates (see results), we have determined that Si for this assay at 450nm
is 16.12mM'\ Enzyme activity was defined in the standard fashion, i.e. one unit 
of enzyme activity is equal to one micromole of product formed per minute. For 
alcohol oxidation by GADH, this is equivalent to one micromole of substrate 
consumed (Chapter 1, Figure 1.1a). Enzyme activity was expressed in milliunits 
per mg protein (umol substrate consumed ' min“^ ’ mg protein ' 10 )^.
Hence the equation is:
activity (mU/mg protein) = r 0.267^
r
I ai j U 6 .I2 J V
At
1000 ^
protein content
16.56
protein content
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The ADH activity in the gastric antrum and body was determined from the mean 
of the activities from the pair of biopsies taken from each site.
5.3.2 Optimisation of assay
Unless otherwise stated, the reaction conditions are the same as those for the 
final assay, with the exception of the parameter being optimised.
5.3,2.1 N, N-dimethyl-4-nitrosoaniline concentration
Unlike a conventional spectrophotometer cuvette, the length of the fluid path 
through which the light beam passes in the microtitre plate reader will vary with 
the volume of fluid in each well. It is therefore necessary to determine an 
accurate estimate of the product of path length and molar absorptivity 
coefficient, and to ensure the relationship between concentration and absorption 
is reproducible over a wide range of NDMA concentrations. The optimum initial 
concentration of NDMA should correspond to a relatively high absorbance 
reading, but still be within the absorbance range that can be reliably estimated by 
the plate reader.
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The absorbance readings at 450nm of serial dilutions of NDMA were 
determined. The volume of solution in each well was the same as the final 
reaction volume (267 microlitres).
S.3.2.2 Serial dilution of biopsy material
To determine that a linear relationship exists between enzyme activity in the 
biopsy specimens and absorbance change, the assay was performed using serial 
dilutions of pooled incubated biopsy specimens. The diluting agent used was 
RPMI 1640. Each subsequent dilution halved the concentration of biopsy 
material in the reaction well.
S.3.2.3 Substrate concentration
Ethanol may not be the naturally intended substrate of GADH. Different ADH 
isozymes have differing affinities (as described by their Michaelis constant) for 
ethanol, and substrate inhibition by ethanol has been described for some 
isozymes of ADH. The GADH activity in gastric biopsies was therefore 
determined using a range of concentrations of several primary alcohols as 
substrate. The alcohols used were; ethanol, n-butanol and n-propanol at 
concentrations of 5, 10, 50, 100, 250 and 500 mM. hi addition, enzyme activity 
was also determined at higher concentrations of ethanol (1, 2 and 3M).
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The optimum concentration of NAD was detennined using ethanol as a substrate 
with NAD concentrations of 100, 200, 500, 1000 and 2000 mM. Pooled biopsy 
specimens were used in all cases.
5.3.2.4 pH
To assess the optimum pH, quantities of PBS were prepared to pH 3.5, 5.4, 6.0, 
6.45, 7.4, 8.0, and 9.7. These were used to prepare the reaction mixture, and 
pooled biopsies were analysed using ethanol as substrate.
5.3.2.5 Homogenisation versus incubation
In ten subjects, four biopsies were obtained as close together as possible in the 
gastric antrum, and were frozen in the usual manner. Two of these biopsies were 
processed by incubation, and the remaining two were homogenised. The biopsies 
that were homogenised were placed individually in a glass Potter- Elvehjem type 
homogeniser with 500ul of RPMI. The biopsy tissue was manually disrupted in 
this homogeniser for 5 minutes. A further 500ul of RPMI was added, removing 
any debris from the homogeniser pestle. The specimens were then centrifuged 
for 5 minutes at 980‘g. The specimen supernatant was used for further analysis. 
This is similar to the homogenisation techniques employed in conventional ADH 
assays (Thuluvath et al., 1994), (Hemandez-Munoz et al., 1990), (Simanowski et
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al., 1998). The activity of each pair of incubated gastric biopsies was then 
compared with the corresponding pair that had been homogenised.
5.S.2.6 Incubation time
Biopsies from ten subjects were incubated in the standard manner. However, 
22ul of incubation fluid was removed after 6, 12, 24, 36, and 48 hours of 
incubation. The fluid obtained from these biopsies at these specific time points 
was pooled, and later analysed to determine if there was a difference in activity 
with differing incubation times.
5.3.2.7 Comparison with other oxido- reductase enzymes
Oxido-reductase enzyme assays that employ conventional UV 
spectrophotometry, based on the absorbance band at 340nm (due to the presence 
of NAD in reduced form (NADH)), often have problems related to specificity. A 
significant background rate of NADH production is often observed in the 
absence of substrate (Zahlten et al., 1980), a phenomenon which has been termed 
“nothing dehydrogenase”. Therefore, a number of other commercially available 
oxido- reductase enzymes were assayed to check the specificity of the assay. 
These enzymes were dissolved in PBS pH 7.4, and 5 Oui of either enzyme 
solution or pooled gastric biopsy incubation fluid was added to the reaction 
mixture. The amount of non- GADH oxido-reductase enzyme used for each well
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was in excess of the amount of GADH normally detected, to increase the 
likelihood of detecting any small influence of these enzymes on the assay.
The amount of enzyme in each well was as follows: 2500mU acetaldehyde 
dehydrogenase, 2900mU lactate dehydrogenase, 3000mU glutamate 
dehydrogenase. The approximate GADH activity of the pooled gastric biopsy 
specimens used for this experiment was ImU per well.
5.3.2.8 Horse liver alcohol dehydrogenase- comparison with conventional 
method
To provide an external standard, a commercial preparation of horse liver ADH 
was also assayed both by the conventional spectrophotometric method of Dalziel 
(Dalziel, 1957), and the NDMA method. Serial dilutions of horse ADH were 
used to provide a range of activities from lOmU to 0.005mU.
To perform the ADH assay by Dalziel’s method, the absorbance change at 
340nm was determined for a 3 ml solution of glycine sodium hydroxide buffer 
(pH 10.0) containing NAD (final concentration 750microM), ethanol (final 
concentration 750mM), and horse ADH. To determine the enzyme activity, the 
absorbance change in a “blank” cuvette (containing the same reaction mixture 
with the addition of 4MP, final concentration 16.7 mM) was subtracted from the 
absorbance change in the “active” cuvette.
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5.3.2.9 Analysis of prokaryotic alcohol dehydrogenase
Fifty microlitres of PBS, pH 7.4 containing either HP suspension (approximately
2.5 million organisms) or yeast ADH (final activity of 3000mU per well, as 
determined by manufacturers’ assay) was used instead of biopsy material, and 
the assay was performed in the standard manner. It became apparent that there 
was a significant change in absorbance in the “blank” wells in addition to the 
“active” wells, and therefore the absorbance change in each pair of wells was 
analysed separately. A range of concentrations of 4MP (18.7, 37.5, 75 and 
150mM) was used in the blank wells of the HP samples to determine the 
concentration at which 4MP inhibited HP ADH activity.
5.4 Statistics
Data were analysed using Student’s t-test, paired or unpaired where appropriate, 
after correction by square root or logarithmic transformation where required. 
Least squares linear regression was used to calculate the gradient of the initial 
portion of the optical density versus time curve, and to examine linear 
relationships between the data. Multiple regression was used to correct for 
potential confounding factors when assessing the effect of HP status, age and the 
duration of freezing (Tabachnick and Fidell, 1996). One- way analysis of 
variance was used to calculate coefficient of variation, using the method 
described by Bland (Bland, 1995). Correlations were performed using Pearson’s 
product moment correlation for normally distributed data, and Spearman’s rank
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correlation for non- parametric data. Comparison of two methods of 
measurement was performed using a Bland and Altman plot (Bland and Altman, 
1986). All tests were 2-tailed, and statistical significance was taken as p<0.05. 
Statistical analyses were performed using SPSS version 9.0 (SPSS Inc, Chicago, 
Illinois, USA) and Minitab version 11.2 (Minitab Inc, Philadelphia, 
Pennsylvania, USA).
5.5 Results
5.5.1 Optimisation experiments
There was a linear relationship between absorbance and NDMA concentration: 
R^=0.997, p<0.001. This is shown graphically in Figure 5.4. The product of path 
length and molar absorptivity coefficient corresponds to the gradient of this 
regression equation, i.e. 16.12mM'\
There was a linear relationship between absorbance change and concentration of 
biopsy material determined by serial dilution. R^=0.998, p<0.001 (Figure 5.5).
Within the range of alcoholic substrate concentrations 10- 500mM, GADH 
activity was greatest with propanol, followed by butanol then ethanol (Figure 
5.6). The enzyme activity with all 3 alcoholic substrates was relatively constant 
between 250 and 500mM. Activity increased in a non- linear fashion with 
ethanol concentrations above 500mM, with a relative plateau between 500mM-
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IM and IM- 2M (Figure 5.6). The optimum NAD concentration was 200microM 
(Figure 5.7). The optimum pH was 6.45 (Figure 5.8).
The enzyme activity observed after incubation was almost identical to that 
observed after homogenisation. There was a strong linear relationship between 
the mean activity of biopsy pairs from the same site, in the same subject, 
prepared by homogenisation and incubation (i=0.89, p<0.001, R^=0.79) (Figure 
5.9). Analysis of the Bland and Altman plot (Figure 5.10) suggests there may be 
a non- significant trend towards over-estimation of the enzyme activity when 
using the incubation method in samples of high activity.
The GADH activity was only minimally influenced by the duration of 
incubation, with longer incubation times being associated with a higher activity 
(GADH activity at 6,12,24, 36 and 48 hours was 21.85,21.60, 23.30, 23.45, 
and 25.40 mU/mg protein, respectively. (Figure 5.11).
The activity of other oxido- reductase enzymes measured in our assay 
contributed to less than 2% of the ADH activity measured (Figure 5.12).
One unit of ADH activity measured by the NDMA method is equivalent to 0.56 
units by DalzieTs method, R^=0.995 (Figure 5.13).
The activity of yeast ADH measured by the NDMA method was much lower 
than the manufacturer’s estimated activity (0.22mU per well by NDMA versus 
3000mU per well from manufacturer’s estimate). The activity of HP ADH by the 
NDMA method was 0.19mU per million organisms. Significant inhibition of HP
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ADH by 4MP was observed at a concentration of 4MP of 75mM. Almost 
complete inhibition was obtained at 150mM (Figure 5.14).
5.5.2 Results obtained with final assay method
Our mean biopsy weight was 7.8mg. There was a strong linear relationship 
between the enzyme activity expressed as per mg of biopsy weight and activity 
per mg protein, = 0.948, p<0.001 (Figure 5.15). Our coefficient of variation 
for paired biopsies was: within assay: 3.0%, between assays: 9.4%
A breakdown of activity by site, substrate type and helicobacter status is shown 
in Table 5.2. ADH activity was higher in the gastric antrum (p<0.001). There 
was a significant difference in ADH activity according to HP status in the gastric 
antrum but not the gastric body (these differences persist after correction for age, 
p<0.005 for antrum and body).
There was a significant but weak correlation with age and ADH activity in the 
gastric body r=-0.30, p<0.05, and gastric antrum r=-0.23, p<0.05 and this 
association persists after correcting for HP status p=0.05.
There was no significant correlation between the length of time biopsies were 
fi’ozen (median 123 days, range 15-392 days) and their subsequent activity 
(r<0.05). This remained insignificant after correction for age and HP status 
(p=0.74).
I
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Figure 5.4 Absorbance at 450nm of serial dilutions of N, N-dimethyl-4- 
nitrosoaniline
This graph demonstrates the linear relationship between absorbance at 450nm 
and concentration of 267ul ofNDMA. Absorbance = 0.01612 ‘ cone (uM). 
R^=0.997, p<0.001. From the Beer-Lambert law we can determine that the 
gradient of the line is equal to the product of path length and molar absorptivity 
coefficient.
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Figure 5.5 Absorbance change of serial dilutions of biopsy material
This graph demonstrates the linear relationship between absorbance change after 
6 minutes at 450nm and biopsy activity (R^-0.998, p<0.001). The activity of the 
undiluted biopsy incubation fluid was arbitrarily defined as 50 units; each 
subsequent dilution halved the concentration of biopsy material in the reaction 
well.
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Figure 5.6 The effect of primary alcohol concentration on enzyme 
activity
These graphs illustrate the effect of varying both the concentration of the primary 
alcohol substrate, and the type of primary alcohol. The enzyme activity was 
varied over a wider concentration for ethanol (upper graph) than for the other 
substrates. The lower graph shows the enzyme activity in detail over the 
concentration range 5 to 500mM.
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Figure 5.7 The effect of nicotinamide adenine dinucleotide (NAD) 
concentration on enzyme activity
This graph illustrates the effect of NAD concentration on pooled biopsy 
specimens, using ethanol as substrate. The optimum NAD concentration is 200 
mM.
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Figure 5.8 The effect of pH on enzyme activity
This graph illustrates the effect of pH on pooled biopsy specimens, using ethanol 
as substrate. The optimum pH is 6.45.
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Figure 5.9 Plot of enzyme activity obtained by incubation and 
homogenization methods
This graph illustrates the linear relationship between the mean activity of paired 
antral biopsies prepared by homogenisation, and the mean activity of paired 
antral biopsies, from the same subject, prepared by incubation. Activity 
(incubated)= 1.0305’activity (homogenized) + 2.1315; (r=0.89, p<0.001, 
R^=0,79)
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Figure 5.10 Bland and Altman plot comparing incubation and 
homogenization methods
This graph shows a Bland and Altman plot (plot of difference between methods 
versus mean activity of both methods). The solid line illustrates the regression 
line. The equation of this line is: difference in activity=1.78- 0.216 mean activity 
This non- significant regression line may suggest a minor trend towards over­
estimation of the enzyme activity when using the incubation method in samples 
of high activity (r=-0.35, p=0.32, R^=0.123). The mean of the difference between 
the methods (95% CÎ) is -2.73 (-14.18- 8.73). The dotted lines illustrate the 95% 
confidence limits. Point A has a disproportionately great influence on these 
parameters. Excluding this point would give the following parameters: difference 
in activity=0.49- 0.086 mean activity; r=-0.23, p=0.55, R^=0.052; mean 
difference (95% Cl) = -1.23 (-8.37- 5.91).
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Figure 5.11 The effect of incubation time on enzyme activity
This graphs illustrates the minimal effect of incubation time in the range 6- 48 
hours on the GADH activity detected in the incubation fluid. The activity at 48 
hours (25.40mU/mg protein) is 16% greater than that at 6 hours (21.85mU/mg 
protein)
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Figure 5.12 Activity of gastric alcohol dehydrogenase compared to other 
NAD dependent oxido-rednctase enzymes
This graph illustrates that the contribution of other oxido-reductase enzymes to 
the activity detected by this assay is negligible.
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Figure 5.13 Horse liver ADH activity by Dalziel’s method and NDMA 
method
This graph illustrates the linear relationship between ADH activity assessed by 
UV spectrophotometry (Dalziel, 1957), and by the NDMA method.
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Figure 5.14 Activity of a suspension of Helicobacter pylori^ with differing 
concentrations of 4 methyl pyrazole
This graph illustrates the effect of varying 4 methyl pyrazole (4MP) 
concentration on Helicobatcerpylori alcohol dehydrogenase (ADH) activity. 
Significant inhibition of activity is apparent at 75mM 4MP, and almost complete 
inhibition at 150mM. The mammalian enzymes (human gastric ADH and horse 
liver ADH) were completely inhibited at 18.7mM 4MP.
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Figure 5.15 Relationship between gastric alcohol dehydrogenase activity 
in biopsy samples when expressed by weight or protein content
This graph illustrates the linear relationship (R^=0.948, p<0 .0 0 1 ) between 
enzyme activity expressed as biopsy weight (mU/mg) and protein content 
(mU/mg protein) in 110 biopsy specimens.
Page 116
Table 5.2 The effect mucosal type (antral or body) and the effect of 
Helicobacter pylori infection, on gastric alcohol dehydrogenase activity
Antrum Body
Overall 10.9 (3.9-17.8) 5.2 (3.7- 10.2)
HP+ve 8.9(2.0-15.4) 6.3 (3.5-12.6)
I  p<0.005 \p=N S
HP-ve 18.3 (8.8-25.0) ^  5.1 (4.3-7.1) }
Gastric alcohol dehydrogenase (ADH) median activity (inter- quartile range) is 
quoted in mU (umol min'^’mg protein "^TO )^. H P- Helicobacter pylori. NS= not 
statistically significant. Gastric antral ADH activity is significantly greater than 
that of gastric body, p<0 .0 0 1 .
Page 117
5.6 Discussion
NDMA is a yellow- green coloured aldehyde- like dye that becomes colourless 
when reduced to its hyroxylamine form by ADH in the presence of NADH.
Dunn and Bernhard, 1971 described its reaction with liver ADH, and Skursky et 
al., 1979 subsequently reported a method for detecting ADH in serum using 
NDMA.
Many of the traditional gastric ADH assays rely on specimens obtained at 
surgical resection (Yin et al., 1997), (Buhler and Wartburg, 1982), (Roine et al., 
1992a), (Hemandez-Munoz et al., 1990), (Roine et al., 1990), (Haber et al.,
1996) or by using non- standard biopsy forceps (Brown et al., 1995), or 
combined biopsies (Thuluvath et al., 1994), giving an average specimen weight 
greater than the one in this study of 7.8mg. Almost all assays employ a 
homogenisation stage. The aim of this study was to develop a method that would 
allow a large number of specimens to be processed more rapidly, and to 
minimise any experimental error due to differences in the completeness of 
homogenisation between samples. The incubation technique, coupled with the 
increased sensitivity of the NDMA assay, allowed reliable detection of ADH in 
the incubation supernatant.
The results obtained from incubation were in close agreement with those 
obtained by homogenisation. There was only a modest increase in enzyme
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activity with an increasing duration of incubation. For convenience, an 
incubation beyond 24 hours was felt to be of only marginal benefit.
Gastric alcohol dehydrogenase can utilise many primary alcohols as substrate, 
and hence the assay was performed with ethanol, butanol, and propanol. 
Although higher activities are seen with the primary alcohols other than ethanol, 
it is the activity with ethanol as substrate that is likely to be of interest to most 
researchers. Likewise, although the enzyme activity rises as ethanol 
concentration increases, the concentrations that are easily achievable in social 
drinking are likely to be of most relevance. The two plateau phases in activity 
versus concentration are likely to represent concentrations at which one isozyme 
of ADH is fully saturated, but where the concentration has not yet reached the 
Km (Michaelis constant) value of other isozymes. The continued rise in
concentration above 3M ethanol may represent Class IE (%) ADH, which is not
saturatable by ethanol.
The variation in gastric ADH activity due to gender, HP status, age and ethnic 
group has been discussed in Chapter 2. These differences have been suggested 
by some to contribute to increased susceptibility to the effects of alcohol. 
Differing ADH activities in different sites in the GI tract, particularly in relation 
to the local activity of acetaldehyde dehydrogenase may have a role in local 
tissue damage and carcinogenesis, because acetaldehyde has been shown to be a 
potential carcinogen (Seitz et al., 1990), (Hori et al., 1997).
In this Caucasian population studied, a small but statistically significant age 
effect was demonstrated. The lower activity of antral ADH in HP positive
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subjects has been noted by others (discussed in Chapter 2), and is probably a 
consequence of a predominantly antral gastritis.
The activity observed with this method for ADH derived from Baker’s yeast was 
markedly below the manufacturer’s published activity (using a standard 
spectrophotometric technique). However, the estimated activity of mammalian 
ADH was similar using the NDMA and the spectrophotometric techniques. This 
may be because the non- mammalian enzyme has less affinity for NDMA. The 
prokaryotic ADH enzymes required higher concentrations of 4MP for inhibition, 
suggesting that they also have a lower affinity for 4MP.
In conclusion, this study has demonstrated a method for assaying ADH in gastric 
endoscopic biopsies which is sensitive, rapid and robust, giving results for 
differences in ADH activity by helicobacter status and age which are similar to 
those found when using more traditional methods.
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Chapter 6: The effect of Helicobacter pylori eradication on blood alcohol 
concentration, gastric emptying, and the systemic delivery of alcohol
6.1 Introduction
It has been noted for some time that when alcohol (ethanol) is administered 
orally there is incomplete delivery of the alcohol dose to the systemic circulation 
(Julkunen et al., 1985), (Di Padova et al., 1987a). This discrepancy is due to pre- 
systemic metabolism (also called first pass metabolism) of alcohol, which must 
occur in either the gastrointestinal tract or the liver (via the portal circulation).
Gastric mucosa contains alcohol dehydrogenase that is capable of metabolising 
ingested alcohol to acetaldehyde (Pestalozzi et al., 1983), (Buhler and Wartburg, 
1982), (Yin et al., 1997). Gastric metabolism of alcohol may therefore account 
for a proportion of the first pass effect. Whether this proportion is clinically 
significant compared with hepatic first pass metabolism is a matter of great 
controversy (Gentry et al., 1994a), (Levitt, 1994a), (Gentry et al., 1994b). 
Helicobacter pylori (HP) infection is associated with lower gastric alcohol 
dehydrogenase (GADH) activity (discussed in detail in Chapter 2).
Eradication of HP has been shown to increase the activity of GADH (Gupta et 
al, 1994), (Simanowski et al, 1998), (Kechagias et al, 2 0 0 1 ). To date, only one 
study has addressed the effect of therapy for HP on alcohol metabolism 
(Simanowski et a l, 1998), suggesting an increase in first pass metabolism 
following HP suppression. However, it failed to take account of gastric
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emptying, or address the unusual pharmacokinetic properties of alcohol. Hepatic 
alcohol metabolism does not obey first- order kinetic principles, and the 
contribution of the liver to pre-systemic metabolism will therefore vary with the 
rate of alcohol delivery to the portal circulation. This will vary with the rate of 
gastric emptying (Kechagias et al., 1998), (Amir et al., 1996). Hence, by acting 
as a reservoir, the stomach can both increase exposure to GADH (Amir et al., 
1996), and increase hepatic first pass metabolism (Holford, 1987). Therefore, HP 
eradication could influence pre-systemic alcohol metabolism both by affecting 
gastric emptying, as well as by increasing GADH activity.
The aims of this study are: 1) To determine if HP eradication alters the amount 
of alcohol reaching the systemic circulation following oral administration, and 2 ) 
By assessing GADH activity and the rate of gastric emptying, this study also 
aims to determine the relative contribution of each of these factors to any 
observed changes.
6.2 Patients and methods
6.2.1 Patients
18 male patients, mean age 42 (range 23- 67), who were attending for upper GI 
endoscopy as a routine part of investigation for dyspepsia, dysphagia, or weight 
loss, were recruited. The criteria for inclusion were: HP positive, male sex, 
Caucasian ethnic origin, age less than 70, and non-malignant upper GI pathology 
that warranted HP eradication therapy on clinical grounds (duodenal or gastric
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ulceration; gastritis; duodenitis; scarring from previous ulceration). Subjects 
were excluded if they had a history of: alcoholism, (current or previous); liver 
disease; malignancy (either in the past, or at index endoscopy), previous gastric 
surgery; other severe illness (diabetes, epilepsy, ischaemic heart disease, 
cerebrovascular disease, severe respiratory disease). They were also excluded if 
they had taken any of the following medications in the preceding 2  weeks: H2 
receptor antagonists, proton pump inhibitors, other anti-ulcer therapies (except 
for simple antacids), aspirin, anticonvulsants, and other medication known to 
significantly affect hepatic metabolism or GADH activity. All subjects gave 
informed written consent and the local ethics committee approved this study. 
This study conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki.
6.2.2 Initial endoscopy
In addition to samples required for diagnostic purposes, a biopsy was taken with 
standard endoscopic biopsy forceps (Olympus FB3K) for histological 
examination from the gastric body and antrum. Two biopsies were also taken 
from both the gastric antrum and body for determination of GADH activity, by 
the methods detailed in Chapter 5. An endoscopic urease (CLO™) test was also 
taken from the gastric antrum. Subjects were considered to be HP positive if the 
CLO test became positive within 24 hours, and there was evidence of HP on 
histology of gastric biopsies.
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6.2.3 Initial administration of alcohol
Subjects were asked to delay taking eradication therapy until this part of the 
study had been performed, which took place within one week of the initial 
endoscopy. Subjects abstained from alcohol for 24 hours, and fasted for 4 hours 
prior to alcohol administration. An intravenous (IV) cannula was inserted, and 
blood was taken for a standard biochemical screen (which was performed by the 
hospital laboratory staff) including liver function tests, and baseline blood 
ethanol measurement. They were given a meal consisting of lOOmls of Ensure 
oral dietary supplement (Abbott Laboratories Ltd., Queenborough, Kent UK) (1 
Calorie/ml), and 2 slices of toast with lOg of butter. Thirty minutes after their 
meal, subjects were given 0.3 g/kg of ethanol, in the form of vodka, given with a 
sufficient volume of pure orange juice (approximately 130- 2 0 0 ml) (0.4 Calories/ 
ml), such that the concentration of ethanol in the beverage was 1 2 % weight/ 
volume. In addition, the alcoholic mixture contained Ig of dissolved paracetamol 
(acetaminophen). Blood was taken from the IV cannula for estimation of blood 
alcohol and serum paracetamol concentrations at the following times: 0,10, 15, 
20, 25, 30, 35, 40, 50, 60, 80, 100, 120, 150, 180 minutes. Both alcohol and 
paracetamol were analysed by enzymatic methods (alcohol- Sigma ADH, 
paracetamol- Cambridge Life Sciences), using a Cobas MIRA analyser (Roche 
Diagnostics, Basel, Switzerlan). The alcohol and paracetamol measurements 
were performed by Mr W Borland (Department of Biochemistry, Glasgow Royal 
Infirmary).
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6.2.4 Eradication therapy
The eradication therapy consisted of seven days of lanzoprazole 30mg twice 
daily, amoxycillin 500mg twice daily, and metronidazole 400mg three times 
daily (all taken orally).
6.2.5 Subsequent endoscopy and alcohol administration
Repeat upper GI endoscopy, with the same biopsy protocol as described for 
initial endoscopy, was performed on average 9 weeks (range 6-17 weeks) after 
commencing eradication therapy to confirm HP eradication. The alcohol 
administration procedure was repeated within two week of the second 
endoscopy. It was performed at the same time of day as the initial study to 
minimise diurnal variation in alcohol metabolism (Palmer et al., 1991) or gastric 
emptying.
The aim of this study is to assess the effect of HP eradication, rather than the 
efficacy of an eradication regime at causing changes in alcohol metabolism. The 
analysis of the results was therefore based on successful eradication rather than 
intention to treat.
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6.2.6 Estimation of total absorbed alcohol dose
As a consequence of its non- linear pharmacokinetics, the area under the curve 
(AUC) for blood alcohol concentration (B AC) is not directly related to the dose 
of alcohol absorbed (Holford, 1987). Increasing the rate of absorption of alcohol 
will increase the AUC, despite the dose remaining constant. In addition, an 
increase in alcohol dose will cause a disproportionately greater increase in AUC 
(Wilkinson, 1980) (discussed in detail in Chapter 3).
The overall alcohol elimination rate can be described in man using the 
Michaelis- Menten equation (Holford, 1987) (see Appendix A.2, Equation 3). 
The equation parameters Vmax (maximum velocity) and Km (Michaelis constant) 
were estimated from the portion of the BAC versus time curve after absorption 
and distribution were complete, using the integrated form of the equation, as 
described by Lundquist (Lundquist and Wolthers, 1958) (see Appendix A.3, 
Equation 6 ). By using these parameters, the total amount of alcohol reaching the 
systemic circulation can be estimated at any given time by using the formula 
described by Gentry et al., 1992 and Lin et al., 1976 (Appendix A.4, Equation 7), 
where the dose absorbed will be proportional to the AUC of elimination rate 
determined by the Michaelis- Menten formula over time for each value of blood 
alcohol concentration.
For reasons discussed in detail later, volume of distribution was not directly 
measured in this study. The volume of distribution was estimated from published 
data (Wagner et al., 1989), (Lands, 1998), (Holford, 1987), and this was used to 
provide an estimate of bioavailability.
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Despite concerns about its validity in relation to total absorbed dose, the AUC of 
BAC versus time is perhaps still the most useful expression of the duration and 
extent of exposure of the body to alcohol, which may be a major factor in 
determining systemic toxicity, and hence the AUC of BAC versus time was also 
calculated.
6.2.7 Gastric emptying
Paracetamol is absorbed in the jejunum but not the stomach, and measurement of 
serum paracetamol concentration can therefore provide usefiil information about 
the rate of gastric emptying (Van Wyk et al., 1990), (Clements et al., 1978). 
Changes in gastric emptying were assessed by comparing both the magnitude of 
the peak paracetamol concentration, and the time to peak paracetamol 
concentration. Subjects remained seated throughout the alcohol administration 
study to minimise changes in gastric emptying associated with posture.
6.3 Statistics
Student’s paired t- test was used to compare subject parameters before and after 
HP eradication. The area under the curve was calculated using the trapezoidal 
method. Correlations were performed using Pearson’s product moment 
correlation for normally distributed data, and Spearman’s rank correlation for 
non- parametric data.
Page 127
Calculations were performed using Excel version 9.0 (Microsoft Corp., Seattle, 
Washington, USA); SPSS version 9.0 (SPSS Inc., Chicago, Illinois, USA); 
Minitab version 11.2 (Minitab Inc, Philadelphia, Pennsylvania, USA). The 
estimation of the parameters of the Michaelis- Menten equation were performed 
using non- linear least squares regression curve fitting software (Curve Expert 
version 1.34, D Hyams, Starkville, Mississippi, USA). All tests were 2- tailed 
and significance was taken as p<0.05.
6.4 Results
The initial endoscopic findings of the 18 subjects are shown in Table 6.1. Three 
subjects withdrew from the study prior to the second endoscopy. Eradication 
therapy was successful in 10 out of the remaining 15 subjects. In those with 
successful HP eradication, GADH activity rose significantly in the gastric 
antrum, pre- eradication 4.79mU/mg protein, post eradication 17.16mU/mg 
protein, p<0.03 , but not the gastric body, pre- eradication 4.70mU/mg protein, 
post eradication 6.07mU/mg protein, p=0.89 (Table 6.2). There was no change 
following successful eradication therapy in AUC for BAC versus time, or in the 
total absorbed dose of alcohol/ volume of distribution, or in the estimated 
bioavailability of alcohol (Table 6.2). There was also no change in the 
magnitude, or time to peak, of the serum paracetamol concentration following 
successfijl eradication therapy, suggesting the eradication of HP did not 
influence the rate of gastric emptying after the test meal (Table 6.2). In the five
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subjects in whom eradication therapy was unsuccessful (Table 6.3), there was no 
significant change in any of these parameters.
There was no significant change in weight following eradication therapy: 
successful eradication group (median); pre-eradication 81.4kg, post eradication 
83.0kg, p=0.39: unsuccessful eradication group; pre-eradication 69.5kg; post 
eradication 71.4kg, p=0.44.
The mean values for blood alcohol concentration versus time before and after 
eradication therapy are shown in Figures 6 .1  and 6.2, for the successful 
eradication and unsuccessful eradication groups, respectively. Corresponding 
values for serum paracetamol are shown in Figures 6.3 and 6.4. The cumulative 
dose of alcohol eliminated per litre of volume of distribution versus time is 
shown in Figures 6.5 and 6 .6 , for the two groups.
There was no correlation in the baseline data between the estimated 
bioavailability and ADH activity in the gastric antrum (r=-0.23, p=0.39), gastric 
body (r=-0.27, p=0.33), or the mean of the body and antrum (r=-0.27, p-0.33). 
Bioavailability correlated with peak serum paracetamol concentration (r=-0.54, 
p=0.02), but not the time of the paracetamol peak (r=-0.26, p=0.30). The group 
in whom HP was successfully eradicated showed no correlation between the 
change in estimated bioavailability and change in gastric ADH activity, or 
change in paracetamol measurements (data not shown). The change in AUC for 
BAC correlated strongly with the change in alcohol dose absorbed/ Vd (r=0.83,
p<0 .0 1 ).
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Table 6.1 Initial endoscopic findings in eighteen male subjects
Endoscopic Diagnosis Number of Subj ects
Gastritis 5
Duodenitis 6
Duodenal scarring 4
Duodenal ulcer 5
Gastric ulcer 1
Gastric erosions 2
Oesophagitis 2
Note that more than one endoscopic diagnosis is recorded for some subjects.
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Figure 6.1 Blood alcohol vs. time- Successful eradication group
Mean blood alcohol concentration versus time curves for the successful 
eradication group. Error bars show the standard error of the mean. There is no 
significant difference in area under the curve pre and post eradication (606 
versus 689 mmol'min, respectively, p=0.36).
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Figure 6.2 Blood alcohol vs. time- Unsuccessful eradication group
Mean blood alcohol concentration versus time curves for the unsuccessful 
eradication group. Error bars show the standard error of the mean. There is no 
significant difference in area under the curve pre and post eradication (556 
versus 506 mmol'min, respectively, p=0.61).
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Figure 6.3 Serum paracetamol vs. time- Successful eradication group
Mean serum paracetamol concentration versus time curves for the successful 
eradication group. Error bars show the standard error of the mean. There is no 
significant difference pre- and post- eradication for the time of paracetamol peak 
(35 versus 32.5 min, respectively, p=0.96), or for the peak paracetamol 
concentration (94 versus 8 6  umol/1, respectively, p=0.62).
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Figure 6.4 Serum paracetamol vs. time- Unsuccessful eradication group
Mean serum paracetamol concentration versus time curves for the unsuccessful 
eradication group. Error bars show the standard error of the mean. There is no 
significant difference pre- and post- eradication for the time of paracetamol peak 
(53 versus 43 min, respectively, p=0.67), or for the peak paracetamol 
concentration (70 versus 77 umol/1, respectively, p=0.84)
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Figure 6.5 Cumulative dose of alcohol eliminated/ volume of distribution 
versus time- Successful eradication group
Mean cumulative amount of alcohol eliminated per litre of volume of 
distribution, for the successful eradication group. Error bars show the standard 
error of the mean. There is no significant difference pre- and post- eradication 
(9.46 versus 10.45 mmol/1, respectively, p=0.17).
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Figure 6.6 Cumulative dose of alcohol eliminated/ volume of distribution 
versus time- Unsuccessful eradication group
Mean cumulative amount of alcohol eliminated per litre of volume of 
distribution, for the unsuccessful eradication group. Error bars show the standard 
error of the mean. There is no significant difference pre- and post- eradication 
(9.07 versus 7.76 mmol/1, respectively, p=0.36).
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6.5 Discussion
This study has demonstrated that a rise in GADH activity does not change the 
pre- systemic metabolism of alcohol. The relative importance of GADH in pre- 
systemic alcohol metabolism, and therefore its role in determining susceptibility 
to alcohol related disease, has been hotly debated over recent years (Gentry et al., 
1994a), (Levitt, 1994a), (Gentry et al., 1994b). Factors affecting GADH activity 
were discussed in detail in Chapter 2 .
Recruitment was deliberately restricted to non- elderly male subjects of 
Caucasian ethnic origin. They were not taking any medication likely to interfere 
with GADH, and a period of several weeks was scheduled between eradication 
therapy and repeat alcohol administration. The test meal (Lin et al., 1976) and 
alcohol concentration (Roine et al., 1991) were chosen to reasonably delay 
gastric emptying, as this is associated with increased pre- systemic metabolism 
(Oneta et al., 1998). The study was designed in this way to maximize the 
likelihood of the subjects having high potential GADH activity post eradication 
and hence a significant gastric pre- systemic metabolism, if this indeed exists, 
and to minimise variation in hepatic alcohol metabolism and gastric emptying. 
The median baseline bioavailability of approximately 60- 65% implies that the 
study design has been successful in facilitating significant pre- systemic 
metabolism.
The discovery that HP eradication increases GADH activity (Gupta et al., 1994), 
(Simanowski et al., 1998), (Kechagias et al., 2001) has allowed researchers an 
opportunity to assess the importance of GADH by increasing its activity.
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Previously, researchers studying gastric first pass metabolism only had the 
opportunity to lower GADH activity with medication (discussed in Chapter 2), 
or alter gastric motility (Amir et al., 1996), (Dziekan et al., 1997), (Kechagias et 
al., 1998), (Oneta et al., 1998). To date there has been only one study, which was 
of a similar size to this study, addressing the effect of HP eradication on alcohol 
first pass metabolism (Simanowski et al., 1998). Its findings were in contrast to 
the present study, as it suggested that treatment for HP was associated with an 
increase in alcohol first pass metabolism (i.e. a fall in alcohol bioavailability). 
However, that study can be criticised on a number of points. Firstly, no attempt 
was made to estimate gastric emptying time. Secondly, an unusual eradication 
regime was given (amoxycillin and ranitidine for 2  weeks), which the authors 
admit is likely to suppress but not eliminate HP, and administration of alcohol 
took place only 5 days after this treatment had stopped. They also failed to take 
account of the non- linear pharmacokinetics of alcohol. In the present study, the 
lack of positive results in the subjects who received eradication therapy but 
remained HP positive suggests that there were no significant effects due to our 
eradication medication.
Frezza et al., 1990 suggested that lower GADH activity in women may account 
for their increased susceptibility to alcohol secondary to higher bioavailability. 
They found a significant correlation between GADH activity and the extent of 
first pass metabolism. No such correlation was identified in the present study, or 
in other studies (Oneta et al., 1998), (Simanowski et al., 1998). However, the 
Frezza study also made the common mistake of assuming that the dose of 
absorbed alcohol could be calculated by methods which are appropriate only to
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first- order drugs (Sweeney, 1990). The AUC may provide a useful marker for 
the extent of exposure of the body to alcohol, but it should not be regarded as 
proportional to the total dose of alcohol absorbed. Later studies by this group 
(Baraona et al., 2001), (Amir et al., 1996), (Roine et al., 1991), (Gentry et al., 
1999), (Lim et a l, 1993), (Di Padova et al, 1992) and other researchers (Lin et 
al., 1976), (Levitt et al., 1997) have employed the integration methods that was 
also used in the present study.
The overall bioavailability of alcohol will vary with the rate of gastric emptying 
(discussed in detail in Chapter 2). Therefore, the stomach may increase first pass 
metabolism purely because it delays the transit of alcohol into the small intestine, 
even without consideration of the effects of GADH. In addition, delayed gastric 
emptying will increase the exposure time of luminal alcohol to GADH. In this 
study, as in others, (Oneta et al, 1998), it was therefore considered crucial to 
have some indication of the rate of gastric emptying. A significant correlation 
between alcohol bioavailability and gastric emptying time was demonstrated. 
Other studies have reported either a direct correlation (Oneta et a l, 1998), 
(Pedrosa et a l, 1996), or a strong association between bioavailability and gastric 
emptying (Amir et al., 1996), (Kechagias et al., 1998), (Dziekan et al., 1997), 
(Levitt et al, 1997). Unmeasured differences in gastric emptying rates may 
account for the different result observed by Simanowski et al., 1998.
In this study, as in many other studies concerned with alcohol first pass 
metabolism, a choice was made not to administer alcohol intravenously (Dziekan 
et al, 1997), (Kechagias et al., 1998), (Mallat et al, 1994), (Lin et a l, 1976),
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(Roine et al., 1991), (Roine et al., 1990), (Roine et al., 1992a), (Palmer et al., 
1991), (Kawashima et al., 1996). The advantage of IV administration is that it 
allows calculation of volume of distribution, hence allowing calculation of total 
dose absorbed, and in situations where there is repeated testing, it may correct 
for differences in metabolic rate or volume of distribution. However, because 
this study is comparing the dose absorbed on two occasions, provided the 
volume of distribution remains constant, then it does not need to calculated in 
order to draw a comparison. An estimated volume of distribution was used to 
provide an estimate of bioavailability, but the accuracy of this estimate does not 
affect the change in bioavailability- this is why the p value for the change in 
absorbed dose/ Vd is the same as that for the change in bioavailability (Tables
6.2 and 6.3).
The other potential advantage of IV administration, namely the correction of day 
to day variability, is difficult to justify with regard to alcohol. In studies where 
alcohol has been administered intravenously prior to an oral dose (Amir et al., 
1996), (Oneta et al., 1998), (Pedrosa et al., 1996), (Pozzato et al., 1994), (Gentry 
et al., 1999), (Battiston et al., 1997), (Casini et al., 1994), (Lim et al., 1993), (Di 
Padova et al., 1992), (Caballeria et al., 1989b), (Simanowski et al., 1998), the IV 
study has not been performed on the same day as oral administration. Whilst this 
minimises any systematic effect on hepatic ADH of a prior alcohol load (e.g. 
depletion of cofactors, altered redox potential), by it will obviously not correct 
for day to day variation in alcohol metabolism. One study (Ammon et al., 1996) 
gave rV and oral alcohol simultaneously, using a heavy isotope technique to 
separately analyse blood alcohol derived from IV and oral routes. This approach
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was flawed, however, as the additional alcohol from the IV route will increase 
hepatic ADH saturation and therefore decrease hepatic FPM.
Studies in which IV administration of alcohol was repeated on the same subjects 
have not shown any systematic change in pharmacokinetic parameters (Amir et 
al., 1996), (Oneta et al., 1998), (Pedrosa et al., 1996), (Gentry et al., 1999), (Di 
Padova et al., 1992), except for some studies in which Cimetidine was given 
(Pozzato et al., 1994), (Battiston et al., 1997). However, despite a change in 
AUC in these studies, volume of distribution remained the same. It was therefore 
felt that a systematic effect on the volume of distribution was very unlikely, and 
that rV alcohol administration was unnecessary.
The aim of this study was to test the hypothesis that GADH significantly 
contributes to alcohol bioavailability. Despite a rise in GADH activity, the 
results showed no overall change in bioavailability. As this was a small study 
(although comparable in size to most other work in this field), the possibility of 
type H error should be considered. However, from interpretation of the 95% 
confidence intervals, these results would be consistent with at most a 7% relative 
decrease (4.5% absolute decrease) in the dose of alcohol absorbed following 
eradication therapy, and hence this study is unlikely to be failing to detect an 
increase in first pass metabolism of any magnitude.
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6.6 Conclusion
Under these test conditions, a rise in gastric alcohol dehydrogenase activity 
following Helicobacter pylori eradication is not associated with a change in total 
dose of absorbed alcohol, and was not associated with a change in gastric 
emptying. This provides Anther evidence to suggest that gastric alcohol 
dehydrogenase is unlikely to play any clinically significant role in the pre- 
systemic metabolism of alcohol. The eradication of Helicobacter pylori is 
unlikely to confer any advantages in terms of decreased systemic exposure to 
alcohol.
Page 144
SECTION 3 STUDY OF THE CHANGES IN HEPATIC BIOCHEMICAL 
TESTS AND MARKERS OF FIBROSIS FOLLOWING 
ALCOHOL WITHDRAWAL
Page 145
Chapter 7: Effect of alcohol withdrawal on liver transaminase levels and 
markers of liver fibrosis
7,1 Introduction
In clinical practice it has been observed that some alcoholic patients deteriorate 
both clinically and biochemically over a few days following withdrawal from 
alcohol. Case reports and studies of alcoholic hepatitis (Sabesin et al., 1978), 
(Helman et al., 1971) also suggest biochemical liver function tests may worsen 
after alcohol withdrawal. However, there have only been a few studies 
addressing hepatic biochemical changes during alcohol withdrawal in subjects 
across the full spectrum of alcoholic liver disease. These studies were mostly 
retrospective, and their results were conflicting (Hemmingsten et al., 1980), 
(Nielsen, 1965), (Marshall etal., 1983), (Salum, 1972)
Abrupt alcohol withdrawal might cause liver damage by several mechanisms, 
such as worsening of hepatic hypoxia, or an increase in cytochrome- dependent 
xenobiotic metabolism, which were discussed in detail in Chapter 1.
Studies of fibrotic markers have shown an increase in collagen metabolites 
following alcohol withdrawal. However, the conclusions of these studies are 
unclear because of difficulties in interpreting the results with the type of assay 
used (Risteli and Risteli, 1995).
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The aim of this study was to determine the pattern of change of standard 
biochemical tests in alcohol withdrawal, and to use non-invasive markers of liver 
disease to look for further evidence of hepatic damage.
7.2 Methods
7,2,1 Patients
Twenty- two male patients (median age 44, range 29-65), all of whom had 
consumed >150g of alcohol daily for >1 year (median 10 years) were recruited 
from inpatient admissions to the alcohol rehabilitation unit at Ruchill Hospital, 
Glasgow. Admissions were asked consecutively to participate in the study, 
provided they were not excluded by the criteria below. Patients were admitted 
for elective alcohol withdrawal, rather than management of liver disease. A 
patient population with clinically compensated liver disease was chosen for this 
study. Acute illness often precipitates alcohol withdrawal in chronic alcoholics, 
and could potentially confound the results. Subjects with evidence of a medical 
condition precipitating alcohol withdrawal or who had hepatic decompensation 
(jaundice, ascites, encephalopathy, or gastrointestinal haemorrhage) at baseline 
were therefore excluded. Patients with evidence of liver disease of another 
aetiology (positive hepatitis A, B, or C serology, positive anti-mitochondrial, 
anti-smooth muscle or anti-nuclear antibody, or a history of gallstones) were 
excluded from the study. These subjects were managed as inpatients for 1 week 
following alcohol withdrawal, and they were asked to return as outpatients
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during the following week. They were withdrawn from the study if they resumed 
drinking. All subjects gave informed written consent and the local ethics 
committee approved this study. This study conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki.
7.2.2 Clinical measurements
Patients were examined daily for signs of liver disease and possible 
complications such as infection, gastro-intestinal bleeding, ascites, oedema or 
pancreatitis. An estimate of body composition was made on admission by 
measurement of body mass index (BMI), triceps skin fold thickness and mid 
upper arm circumference. The percentage body fat was calculated from these 
measurements (Lean et al., 1996). In addition, daily measurement of alcohol 
withdrawal symptoms were performed by ward nursing staff, using the Clinical 
Institute Withdrawal Assessment Scale for Alcohol (revised):- CIWA-Ar 
(Sullivan et al., 1989). Alcohol intake was assessed on the basis of clinical 
history obtained by medical and nursing staff experienced in alcohol 
dependence.
7.2.3 Laboratory measurements
7.2.3.1 Standard hospital laboratory tests
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The first blood samples were obtained on hospital admission within 72 hours of 
last alcohol consumed (median 22 hours). These samples were processed as part 
of routine hospital assays by the hospital laboratory personnel for the following: 
alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), amylase, 
aspartate transaminase (AST), bilirubin (BR), blood ethanol, coagulation profile, 
creatine kinase (CK), full blood count, gamma glutamyl transferase (GGT), urea 
and electrolytes. These were repeated daily for seven days. The patients were 
usually discharged at day 7, and returned on day 14 to repeat these tests. The 
arbitrary criteria used in this study to define worsening of liver function tests 
were: a 50% rise from the baseline value, with the elevated result outwith the 
normal laboratory reference range. This was chosen prior to commencement of 
the study in an attempt to exclude values that rose simply as a result of minor 
biological and analytical variation. Continuing abstinence was assessed by blood 
alcohol measurement, random breath alcohol measurement, and self- reporting.
7.2.3.2 Markers of hepatic fibrogenesis
Plasma samples from day 1, 7 and 14 were frozen at -20°C within 4 hours of 
being obtained, and later analysed in one batch, to minimise analytical variation. 
Two different commercial radio-immunoassay kits were used for amino-terminal 
pro-collagen HI peptide (PIUNP). They were manufactured by Orion Diagnostica 
(Espoo, Finland), and Cis Bio International (Paris, France). Tissue inhibitor of 
metalloproteinase-1 (TIMP-1) was assayed using a commercial colorimetric 
ELISA assay from Amersham Life Science (Buckinghamshire, England). All
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plasma samples were analysed in duplicate. Our intra-assay coefficients of 
variation for these assays were: TIMPl:- 2.9%, PHINP (Orion):- 4.8%, PIUNP 
(Cis);- 4.8% at levels measured in the present study. Plasma from 11 healthy 
age-matched males who had no history of excess alcohol consumption or 
physical illness was used to provide a normal range for PIUNP and TIM Pl.
The Orion assay, which uses an antibody to human PIUNP, is specific for the 
intact pro-collagen peptide in human serum (Risteli et al., 1988), and is regarded 
as a marker for collagen synthesis (Schuppan et al., 1995). Two hundred 
microlitres of the plasma sample were mixed with a known amount of ^ ^^ I 
labelled PIUNP and then with PIUNP rabbit anti serum. The rabbit antiserura- 
PIHNP complex was separated by addition of bovine anti- rabbit antibody bound 
to plastic beads that were retained after aspirating the remainder of the fluid after 
centrifugation. The residual radioactivity is therefore inversely proportional to 
the amount of PIUNP present in the plasma sample. Dilutions of a standard 
PIUNP solution provided by the manufacturer were used to create a curve of 
radioactivity versus PUCNP concentration to allow determination of plasma 
PDINP concentration from corresponding radioactivity counts.
The Cis assay uses an antibody to bovine PIUNP and it is sensitive for both 
intact PIUNP and smaller PIUNP fragments in human serum (Rohde et al.,
1979). It is regarded as a marker for both collagen synthesis and degradation 
(Schuppan et al, 1995). The assay tubes supplied by the manufacturer are pre­
coated with PniNP antibody. Twenty microlitres of plasma were added to each 
tube. After a period of incubation and décantation of the sample fluid, ^^ I^
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labelled anti-PmNP antibody was added. After further incubation and 
décantation, the activity in each tube was measured. This is proportional to the 
amount of labelled antibody- PHINP- solid phase antibody complex present, 
and hence the radioactivity varies directly with the amount of PIUNP in each 
plasma sample. Measurement of the activity of dilutions of the manufacturer’s 
standard was used to construct a curve from which plasma PIENP concentration 
could be determined.
For both radioimmunoassays, activity was measured on a Beckman- Coulter LS 
gamma counter (Beckman Coulter Ltd., High Wycombe, Buckinghamshire,
UK), with integrated software that performed calculations for the standard curve.
The TIMPl assay is a colorimetric ELISA assay that uses a 96- well microtitre 
plate method. The wells of the plate supplied by the manufacturer are coated 
with anti human TIMPl antibody. The plasma samples were diluted with assay 
buffer to a dilution of 1:10 for control subjects, and a dilution of 1:20 (or higher 
if required) for the alcoholic subjects. One hundred microlitres of the diluted 
plasma sample or dilutions of the manufacturer’s standard were added to each 
well. After incubation and aspiration, a solution of TIMPl antibody conjugated 
with horseradish peroxidase (HRP) was added. After further incubation and 
aspiration, 3, 3’,5, 5’ -tetramethylbenzidine was added. This is oxidised by HRP, 
undergoing colour change. The amount of peroxidase enzyme (present as a HRP 
labelled antibody- TIMPl- solid phase antibody complex), and hence the extent 
of colour change, is therefore proportional to the amount of TIMPl in the plasma 
sample. After further incubation, the HRP reaction was terminated by sulphuric
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acid, resulting in a further colour change. The absorbance at 450nm was 
measured using a Dynatech MR5000 automated microtitre plate reader 
(Dynatech Labs Ltd., Billinghurst, West Sussex, UK). An absorbance versus 
concentration curve was obtained from dilutions of the manufacturer’s standard, 
and integrated software was used to estimate the sample TIMPl concentrations 
from the standard curve.
7.3 Statistics
In the comparison of baseline data, unpaired normal data were analysed using 
Student’s t-test, after square root of logarithmic transformation, where 
appropriate. Non-parametric data were analysed using the Mann-Whitney U 
Test. Estimation of the 95% confidence interval for prevalence, and calculation 
of the coefficient of variation by one- way analysis of variance, were performed 
by the methods described by Bland (Bland, 1995), For the analysis of repeated 
measures data, within-subjects analysis of variance was used (Tabachnick and 
Fidell, 1996). All tests were two- tailed, and statistical significance was taken as 
p<0.05. Statistical analyses were performed using SPSS version 9.0 (SPSS Inc, 
Chicago, Illinois, USA) and Minitab version 11.2 (Minitab Inc, Philadelphia, 
Pennsylvania, USA).
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7.4 Results
Data were analysed on an intention to include basis. Twenty- one (95%) of the 
subjects remained in the study for the first week to complete the initial intensive 
assessment phase, and 13 subjects (59%) remained on Day 14.
7.4.1 Biochemical liver function tests
Gamma GT, bilirubin, ALP, and CK all tended to improve or remain the same in 
the seven days following alcohol withdrawal (data not shown). Aspartate amino­
transferase and ALT also tended to improve in the majority of subjects (Figure 
7.1), and there was no significant change in transaminase levels when the group 
was considered as a whole, but a number of subjects did show a marked 
worsening in liver transaminase levels (Figure 7.2).
The change in transaminases was of similar proportion for AST and ALT. Using 
the pre-defined criteria described above we separated the subjects into 2 groups, 
shown graphically as an improving transaminase group (Figure 7.1) and as a 
worsening transaminase group (Figure 7.2). Seven out of 22 subjects enrolled 
showed a worsening in transaminases (32%, 95% confidence interval 12%- 
51%). Despite a rise in ALT, subject A in Figure 7.1 was included in the 
improving transaminase group as he did not meet the pre- defined criteria for the 
other group.
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There was no statistically significant difference between the groups with respect 
to the baseline biochemical, haematological, or clinical parameters (Table 7.1). 
The normal or mildly elevated baseline biochemical results for both groups are 
consistent with our intention to recruit subjects with clinically compensated liver 
disease.
The group with worsening transaminases received significantly greater amounts 
of chlordiazepoxide (median 140mg per day) during the first week of admission 
compared to the remaining subjects (median 36mg per day), p~0.003. The 
CIWA scores were not different between the two groups (median 16, worsening 
transaminase group, vs. 12, improving transaminase group, p=0.3).
Only one subject received paracetamol containing medication (subjects in 
Figure 7.2). He took a total of Ig of paracetamol on days 3 ,4 ,6  and 8, and 2g on 
day 7. He had the most marked transaminase rise of any subject in this study.
The rate of complications during admission was similar in the two groups, all of 
which were respiratory infections (one of seven in the worse transaminase group 
versus three of fifteen in the improving transaminase group, p>0.9).
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Figure 7.1 Change in serum alanine amino transferase following alcohol 
withdrawal- improving transaminase group
This graph shows the serum ALT levels measured for seven days after alcohol 
withdrawal in the fifteen subjects with improving hepatic transaminases (ALT 
reference range 5- 40 U/1). Subject A showed a transaminase rise but did not 
meet pre- defined criteria for inclusion in the worsening transaminase group (see 
text).
Page 155
450 -1
400 - Subject B
350 -
300 -
e  250 -
^  200 -
150 -
100 -
50 -
2 5 641 3
Time after admission for aicohol withdrawal (days)
Figure 7.2 Change in serum alanine amino-trans(erase following alcohol 
withdrawal- worsening transaminase group
This graph shows the serum ALT levels measured for seven days after alcohol 
withdrawal in the seven subjects with worsening hepatic transaminases (ALT 
reference range 5-40 U/1). Subject B was the only subject to have taken 
paracetamol (see text).
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Table 7.1 Comparison of day one clinical and laboratory parameters 
between the group of subjects with worsening transaminases and the others
vvwvwvw¥vvww«wnnriv«¥WWv«vvvivJSrrtV¥yvvvmwftvvvwVÉVwv¥VVVWVV¥V>n(vvv^^
Baseline clinical, 
biochemical or
Age (years)
Alcohol consumed daily (g) 
Years of alcohol abuse 
Body fat (percentage) 
Cigarettes smoked per day** 
Duration of abstinence prior 
to admission (hours)
Blood ethanol (mg/dl) ** 
Albumin (g/1)
AST (U/1)
ALT (U/1)
Bilirubin (jumol/l) 
Gamma-GT (U/1)
Alkaline Phosphatase 
Haemoglobin (g/1)
Amylase
Creatine kinase (U/1)
White blood cell count 
(xlO^/litre)
Prothrombin Time (seconds) 
PIUNP (U/ml, Cis method) 
PIUNP (ug/1 Orion method) 
TIMPl (ng/ml)
Group with
worsening
transaminases
Group without
worsening
transaminases
p value
42 (9.0) 45 (11.5) 0.56
358 (129) 362(126) 0.95
11 (1.75- 17)* 10(4- 20)* 0.47
22 (6.3) 18(5.9) 0.16
20(0-40)* 20(9-35)* 0.97
6.5(1.6-31.5)* 24(13-45)* 0.12
0 (0- 147.2)* 0(0-36.5)* 0.96
42 (4.0) 44 (4.4) 0.47
60 (32- 120)* 50(31.0- 134.0)* 0.99
75(32-183)* 43 (28- 96)* 0.49
13 (6- 19)* 8 (5- 15)* 0.37
178(66-309)* 69(53-233)* 0.51
192(53) 216(51) 0.39
146 (9.5) 154(9.8) 0.10
160(55) 213 (132) 0.84
81 (71- 137)* 49 (38- 97)* 0.21
6.8 (5.9- 9.5)* 6.6 (5.5- 8.1)* 0.58
12 (0.6) 12.4 (0.7) 0.37
0.36 (0.30- 0.74)* 0.46(0.31-0.51)* 0.64
2.82 (1.11-5.67)* 2.44(1.76-3.52)* 0.74
1108(422) 1268 (418) 0.90
Data shown are means with standard deviation in brackets, except: *where data 
are non- parametric, and medians are shown with inter-quartile range in brackets. 
Two -sample (unpaired) Student’s t-test performed throughout (with 
transformation, if appropriate), except: ** Mann- Whitney U-test.
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7.4.2 Markers of hepatic fibrogenesis
The TIMPl levels were markedly higher in the alcoholic group than in the 
control group (mean 1177 vs. 227ng/ml, p<0.001). The PIUNP concentrations 
from the alcoholic patients were significantly lower than in control subjects in 
the Cis assay (median 0.43 vs. 0.53 U/ml, p=0.03), but not in the Orion assay 
(median 2.57 vs. 3.23 ug/1, p=0.96), implying that the difference between these 
groups is predominantly because of the PIUNP fragments (Figure 7.3).
There was an increase in the PUMP levels following alcohol withdrawal in both 
assays (Orion p<0.02, Cis p<0.01). The percentage median increase was: Orion 
44% and 75%, Cis 10% and 42% at days 7 & 14, respectively. As the major rise 
was seen with the Orion assay, this would be consistent with a rise mainly 
caused by intact PUMP. The TIMPl levels did not change following alcohol 
withdrawal (p=0.22), (Figure 7.3).
There was no significant difference between the group with improving 
transaminases and the others with respect to day 1 TIMPl or PUMP measured 
by either assay (Cis median 0.36U/ml vs. 0.46U/ml, p=0.64; Orion median 
2.82ug/l vs. 2.44ug/l, p=0.74; TIMPl mean 1108ng/ml vs. 1268ng/ml, p=0.9, in 
worsening and improving transaminase groups, respectively).
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Figure 7.3 Markers of hepatic fibrogenesis following alcohol withdrawal
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7.5 Discussion
The pathophysiology of hepatic damage in alcoholism is not fully understood. 
However, there is evidence for mechanisms by which hepatic damage may occur 
in alcohol withdrawal, which were discussed in Chapter 1.
The final outcome of long-term liver damage in alcoholic liver disease is 
cirrhosis. A large proportion of the collagen deposited, especially in the early 
stages of cirrhosis, is type IH (Popper and Udenfriend, 1970). The precursor 
molecule of type HI collagen, type IH procollagen, is secreted with peptide 
extensions called propeptides (PIUP) attached to the amino (PIUNP) and carboxy 
(PmCP) terminals. Intact PIUNP is released when procollagen molecules 
aggregate to form the type lU collagen fibre (Prockop et al., 1979). However, 
some PIUNP is not released from collagen after the collagen fibre has been 
formed. Type lU collagen fibres with PIUNP still attached have been 
demonstrated in primate liver (Sato et al., 1986a). If collagen to which PIUNP 
remains attached is subsequently degraded, then smaller fragments of PIUNP 
may be released. Thus, a PIUNP assay that is sensitive to both intact PIUNP and 
PIUNP fragments reflects both synthesis and degradation (the Cis assay) (Hahn, 
1984; Schuppan et al., 1995). Assays measuring intact PIUNP only (the Orion 
assay) reflect mainly collagen synthesis (Risteli et al., 1988; Schuppan et al., 
1995). Plasma PIUNP levels correlate well with hepatic prolyl hydroxylase 
levels (Torres-Salinas et al., 1986). Direct mathematical comparison of the two 
assays was not possible, but by comparing the pattern of changes in these two
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assays, this study has attempted to determine whether a change in PIUNP is a 
result of changes in intact PUINP or PIUNP fragments. There was no assay 
available to measure PIUNP fragments alone.
The PIUNP can be metabolised by hepatic sinusoidal cells (Smedsrod, 1988), 
and serum levels may therefore be affected by changes in clearance resulting 
from a decrease in hepatic blood flow during alcohol withdrawal.
Failure to degrade excess collagen is important in the development of hepatic 
cirrhosis. The role of TIMPl in inhibiting collagen degradation was discussed in 
Chapter 1. There is good evidence that plasma levels of TIMPl give an accurate 
reflection of liver collagen metabolism, when other serious systemic diseases can 
be excluded. Hepatic collagenase activity decreases as hepatic fibrosis progresses 
(Maruyama et al., 1982). Plasma TIMPl levels correlate with fibrosis scores on 
liver biopsy (Murawaki et al., 1993; Murawaki et al., 1997). Plasma TIMPl (and 
PIUNP) concentrations rise as alcoholic liver disease progresses in histological 
severity (Sato et al., 1986b; Nouchi et al., 1987; Li et al., 1994). Plasma TIMPl 
levels are not known to be influenced by hepatic blood flow.
Although there was no overall change in transaminases following alcohol 
withdrawal when considering all the subjects, there was a subset showing a 
marked transaminase increase. The subject with the largest transaminase rise was 
the only subject to consume paracetamol, albeit at modest doses. The potential 
for paracetamol-induced hepatotoxicity (Lieber, 1993) might therefore be 
markedly increased, being manifest even if a dose well below the recommended
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daily maximum dose was ingested at a critical time following alcohol 
withdrawal.
A large retrospective Scandinavian study (Salum, 1972) showed an increase in 
AST and ALT in 8.7% and 7.0% respectively of subjects withdrawing from 
alcohol. However, liver function tests were only checked on the basis of clinical 
need, and in most subjects these were not checked on more than two occasions 
during the first week of withdrawal. They found that an elevation in 
transaminases was associated with more severe symptoms of delirium tremens, 
which is supported by the finding in the present study of a greater requirement 
for benzodiazepines. The worsening transaminase group are likely to have 
experienced a symptomatically more severe alcohol withdrawal despite similar 
CIWA scores, because they required more benzodiazepines, which will tend to 
reduce their CIWA score. Sympathetic over-activity contributes to the symptoms 
observed in alcohol withdrawal and can further increase hepatic oxygen demand 
(Hadengue et al., 1988) and hence those with more severe symptoms may also 
have a greater degree of hepatic ischaemia resulting in altered transaminases.
A retrospective study of liver function tests and liver biopsy findings in alcohol 
withdrawal suggested that those with worsening liver function tests might have a 
histologically more severe disease (Marshall et al., 1983). The retrospective 
nature of that study may have introduced bias. In contrast, in the present study, 
no difference in biochemical or clinical parameters was found to suggest the 
subgroup with worsening transaminases had more severe disease. It was felt
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unethical to perform liver biopsy in these subjects with clinically compensated 
disease.
The control subjects in this study appear to have a higher level of PUINP 
fragment than alcoholic subjects on day 1. This observed difference may have 
resulted from a decreased collagen degradation in alcoholics whilst still drinking, 
which would be consistent with the findings of increased serum TIMP in 
alcoholics. Lieber’s group also noted a higher PUINP level in controls versus 
alcoholics with fatty liver when using an assay that was very sensitive for PIUNP 
fragments, but not when using a different assay which was less sensitive (Sato et 
al., 1986b; Nouchi et al., 1987; Li et al., 1994). Lieber’s group has also shown 
that alcoholics have an increase in PIUNP following alcohol withdrawal (Nouchi 
et al., 1987; Li et al., 1994). However, these studies did not employ an assay 
exclusively for intact PIUNP and were hence unable to conclude if the observed 
changes were likely to be due to intact peptide or peptide fragments.
This study demonstrates a rise in PIUNP following alcohol withdrawal that is 
likely to be due to intact PIUNP. Although this may imply increased 
fibrogenesis, it may reflect decreased hepatic clearance. The marked increase in 
TIMPl in alcoholics compared to controls suggests that there may be significant 
inhibition of collagen degradation even in this group of patients with clinically 
compensated disease.
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7.6 Conclusions
These results suggest that in alcoholics with clinically compensated liver disease, 
alcohol withdrawal is usually accompanied by an improvement in liver 
transaminase levels. However, a minority of subjects show a worsening of 
transaminases. The period following alcohol withdrawal may be a time of 
marked increased susceptibility to the effects of even small amounts of 
paracetamol. Although the changes observed in transaminases and PIUNP are 
small and not associated with major differences in short-term clinical outcome, 
they may reflect mild liver injury and either a minor increase in fibrosis or a 
decrease in hepatic clearance. The cumulative effect of repeated episodes of 
withdrawal may be important, and hence further studies looking at the effect of 
gradual withdrawal of alcohol on clinical and biochemical parameters would be 
of value. The most striking observation is the markedly increased plasma TIMPl 
levels in these alcoholics compared with controls, supported by the finding of 
decreased PIUNP fragments, suggesting that decreased collagen degradation may 
be present prior to the development of clinically overt liver disease.
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SECTION 4 CONCLUSIONS
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Chapter 8-Conclusions
This thesis has three major conclusions. Firstly, it concludes that a colorimetric 
assay based on the reduction of N, N-dimethyl-4-nitrosoaniline (NDMA) by 
alcohol dehydrogenase in the presence of an alcoholic substrate offers significant 
advantages over conventional ultraviolet spectrophotometric methods for the 
detection of alcohol dehydrogenase. The NDMA method developed in his thesis 
is sensitive, specific, robust, and can be readily applied to the detection of gastric 
alcohol dehydrogenase (GADH) activity in the small amount of tissue in 
standard endoscopic gastric biopsies. Use of an incubation stage to process the 
biopsies allows the preparation time associated with a homogenisation stage to 
be eliminated, without a significant loss in the enzyme activity detected.
Secondly, it has been demonstrated that a rise in gastric alcohol dehydrogenase 
activity îoWow'mg Helicobacter pylori eradication is not associated with a change 
in total dose of absorbed alcohol, and was not associated with a change in gastric 
emptying, despite using test conditions designed to maximise any potential first 
pass metabolism of alcohol as a consequence of GADH activity. This suggests 
that that this enzyme plays at most a minor role in determining alcohol 
bioavailability. The eradication o f Helicobacter pylori is unlikely to confer any 
advantages in terms of decreased systemic exposure to alcohol.
Thirdly, the study of alcoholics with clinically compensated liver disease 
suggested that alcohol withdrawal is usually accompanied by an improvement in 
liver transaminase levels. However, a minority of subjects show a worsening of 
transaminases, and there was evidence of an increased susceptibility to the
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effects of small amounts of paracetamol ingested during the withdrawal period. 
The changes observed in transaminases and markers of hepatic fibrogenesis were 
small and not associated with a difference in short-term clinical outcome. 
However, these changes may reflect mild liver injury and either a minor increase 
in fibrosis or a decrease in hepatic clearance. The cumulative effect of repeated 
episodes of withdrawal may be important, and hence further studies looking at 
the effect of gradual withdrawal of alcohol on clinical and biochemical 
parameters would be of value. The markedly increased plasma TIMPl levels in 
these alcoholics compared with controls, supported by the changes observed in 
procollagen HI peptide, suggesting that decreased collagen degradation may be 
present prior to the development of clinically overt liver disease.
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Appendix: Equations relating to alcohol pharmacokinetics
A.1 The Widmark Equation
This equation represents the earliest attempt to describe the elimination of 
alcohol mathematically, and was based on the assumption that the elimination 
rate of alcohol is constant regardless of the blood alcohol concentration 
(Mellanby, 1919).
A= p ■ r * (Ct + p t) (1 ) The Widmark equation
Where A= amount of alcohol absorbed, Ct= blood concentration at a given time 
t, p= body weight, p is Widmark’s constant (equivalent to the gradient of the 
linear part of the BAG versus time curve), and r= fraction of body weight in 
which alcohol is distributed. Volume of distribution is equivalent to p multiplied 
by r, and the (hypothetical) dose at time zero (denoted Co) will equal the amount 
of alcohol absorbed divided by the volume of distribution. This equation 
assumes absorption and distribution is complete by time zero. The equation 
therefore becomes:
C o=C T + P 't  (2)
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A,2 The Michaelis- Menten equation
This equation describes the enzyme velocity (V) (which, in turn can be 
considered as the rate of generation of product, or the rate of consumption of 
substrate), where S is substrate concentration, Vmax is maximum enzyme 
velocity, and Km is the Michaelis constant, defined as the substrate concentration 
required to produce a reaction rate which is half of Vmax (and which is therefore 
also a measure of enzyme- substrate affinity).
V = ^ (3) The Michaelis- Menten equation
A 3 Derivation of the integrated form of the Michaelis- Menten equation
The reaction velocity is equal to the rate of change of substrate concentration 
with time, hence:
dS Vmax • S 
dt Km + S
where t is time. By inversion:
(4)
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dt _  Km “t" S 
Vmax - S
V— s '^ v — S ^y  max • a  V max • O /
= J ( ^ = — + — ws
* ‘ Vmax ■ S Vmax '
t = lnS- — + - ^ + A
Vmax Vmax
At time zero (to), S=Sq, hence:
0 = In So 1 h k
Vmax Vmax
, , _ Km SoAr = “ ln So-
Vmax Vn
Putting this back into equation (5) gives:
t = l n S - ^  + - ^ - ln S o .  ^
Vmax Vmax Vmax Vmax
s
=:> Vmax * t = S ~  So + Km * In----
So
Where ln= natural logarithm. As we are interested in the decline of S, rather than 
an increase, the rate of change gives us a negative velocity, hence the equation 
becomes:
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Vmax * t = So - S + Km • 111---
S
t = l So-S+Km-ln-^ ^
(6)
Vn
With this equation, we can estimate parameters for So, Km and Vmax using non­
linear curve fitting software, by plotting S and t.
A 4 Estimating the total dose of alcohol absorbed by using the Michaelis- 
Menten equation
The amount of a substance that has been delivered system!cally by any given 
time point must equal the amount present in the body compartment(s) plus the 
amount eliminated. For a single compartment model, this can be represented as:
At-Vd'St + Et
Where, at time t, At=amount of substance delivered systemically, Vd= volume of 
distribution, St= the concentration of the substance (or substrate) in the 
compartment fluid and Et= amount eliminated.
As described by Gentry et al., 1992 and Lin et al., 1976, for a drug that obeys 
Michaelis- Menten elimination kinetics, by integrating the Michaelis- Menten 
equation for all values of S fi’om to to time t:
A = Vd' ft St • VmaxSt+ ---------JoKm + St
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Once absorption is complete, and the substance has been eliminated completely, 
St will equal zero, and the equation therefore becomes;
A = (7)
JoKin + St
A.5 Relationship between total bioavailability and concentration
Total bioavailability is the product of hepatic bioavailability (HB), and the 
fraction of orally administered dose being absorbed by the gut (f).
TB = HB f
Hepatic bioavailability (HB) is the ratio of amount of substance leaving the liver 
relative to amount entering it.
_ amount leaving liver
XID —----------------------- ;-------------
amount entenng liver
amount leaving liver
Q[s]
_ Q • [s]- amount metabolised
q ¥ ]
I i n _ Q [ s ] - C l T [ s ]
Q[S]
Page 173
Where total hepatic clearance is CIt, Q is liver portal venous flow, and S is 
substrate concentration.
In systems approaching hepatic enzyme saturation, and in the absence of 
significant protein binding, total hepatic clearance (CIt) is related to intrinsic 
hepatic clearance (CIint) thus:
Q Clmr
Q + CIint
Substituting this into equation (8) gives:
Q " CliNT
=>HB = 1 —
(9)
HB = 1 -
HB =
Q + CIint
Q
Q + CIint
Intrinsic hepatic clearance (CIint) is a fianction of hepatic enzymatic activity and 
for alcohol can thus be described in terms of the Michaelis- Menten equation:
. amount removedclearance  --------------- :-----
concentration
Therefore, over a given unit of time.
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Vmax ' S
Clrar =  j^ ia ± S .
s
=> CliNT =
Vn
Km + S
Substituting this into (9) gives;
QHB
Q  +  Cl IN T
HB =
Q +
V .
Km +  S
Q * K ra  +  Q ’ S +  V i
Km +  S
HB
HB
Q ( K m  +  s)
Q(Km + s)+ V,
1
1 + (10)
Q(Km + s)
With increasing alcohol dose Km, Vmax, and Q are relatively constant (with 
respect to hepatic bioavailability). Therefore:
r \
1
=  1Lim
S —^ 00 1 + Vn
q (k ™+s)
i.e. the hepatic bioavailability will increase towards unity (100%) with increasing 
substrate concentrations.
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